



UNIVERSIDADE FEDERAL DE ALAGOAS
FACULDADE DE MEDICINA
PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS MÉDICAS

Thaysa Kelly Barbosa Vieira Tomé

**Associação entre ritmo circadiano, câncer e diabetes utilizando ferramentas da
bioinformática**

Maceió
2021

THAYSA KELLY BARBOSA VIEIRA TOMÉ

Associação entre ritmo circadiano, câncer e diabetes utilizando ferramentas da bioinformática

Exame de Defesa do Mestrado apresentada ao Programa de Pós-graduação em Ciências Médicas da Universidade Federal de Alagoas-UFAL, como parte das exigências para a obtenção do título de Mestre em Ciências Médicas.

Área de Concentração: Estudos clínicos e laboratoriais em ciências médicas

Orientador: Prof(a). Dr(a). Carlos Alberto de Carvalho
Fraga

Coorientador: Prof(a). Dr(a).Carolline de Sales Marques

Maceió
2021

Catálogo na fonte
Universidade Federal de Alagoas
Biblioteca Unidade Palmeira dos Índios
Divisão de Tratamento Técnico

Bibliotecária: Livia Silva dos Santos – CRB-4 - 1670

T855a Tomé, Thaysa Kelly Barbosa Vieira
Associação entre ritmo circadiano, câncer e diabetes utilizando
ferramentas da bioinformática/ Thaysa Kelly Barbosa Vieira Tomé. - 2021.
100 f. : il.

Orientador: Carlos Alberto de Carvalho Fraga.

Coorientadora: Carolline de Sales Marques.

Dissertação (Mestrado em Ciências Médicas) – Universidade Federal de Alagoas. Faculdade de Medicina. Programa de Pós-Graduação em Ciências Médicas, Maceió, 2021.

Bibliografia: f. 80 – 85

1. Ritmo circadiano. 2. Síndrome metabólica. 3. Diabetes. 4. Câncer. I.
Título.


CDU: 616

Folha de Aprovação

Thaysa Kelly Barbosa Vieira Tomé

Associação entre ritmo circadiano, câncer e diabetes utilizando ferramentas da bioinformática

Dissertação submetida ao corpo docente do
Programa de Pós-Graduação em Ciências
Médicas da Universidade Federal de Alagoas e
aprovada em (data).



Prof.Dr Carlos Alberto de Carvalho Fraga

UFAL/ FAMED

Orientador(a)



Carolline de Sales Marques

UFAL/ FAMED

Coorientador(a)

Banca Examinadora:



André Luiz Sena Guimarães

UNIMONTES/ODONTOLOGIA


Examinador externo



Juliana Célia de Farias Santos

UFAL/ FANUT

Examinador interno



Fabiana Andréa Moura

UFAL/ FANUT

Examinador interno

AGRADECIMENTOS

Agradeço a Deus por ter me dado forças e me guiado até aqui, por me segurar quando pensei em desistir, a Tales que me apoiou em todos os momentos e teve paciência com todas as etapas percorridas, a Isa que mesmo em meu ventre já me acompanhava nesta jornada e após o nascimento, onde tive que abdicar de momentos ao seu lado para me dedicar ao mestrado, aos meus pais e irmã por todo apoio incondicional, ao meu orientador que teve paciência, que me guiou com maestria até o final o meu muito obrigada.

RESUMO

Introdução: A tumorigênese é afetada pelos genes do relógio. Alterações da expressão dos genes do relógio podem aumentar a susceptibilidade ao câncer através dos efeitos nos mecanismos biológicos que regulam o dano e reparo ao DNA, o metabolismo energético, crescimento e morte celular em tecidos neoplásicos. **Objetivo:** analisar a associação do ritmo circadiano, diabetes tipo 2 e câncer. **Metodologia:** O estudo é uma meta-análise realizada em amostras de tecido de paciente com diabetes tipo 2 e amostras de tecido normal, genes relacionados ao ritmo circadiano e dados do transcriptoma associado ao câncer de mama, bexiga, fígado, pâncreas, cólon e reto usando a integração de perfis de expressão gênica com biomolecular em escala de genoma redes em amostras de diabetes, os bancos de dados pesquisados foram o Pubmed e TCGA. Foram utilizados os descritores ritmo circadiano, diabetes tipo 2 e câncer em inglês com operadores booleanos *and* ou *or*. **Resultados:** KLF10, NTKR3, IGF1, USP2, EZH2 foram regulados negativamente em amostras de diabetes tipo 2 e câncer, enquanto ARNTL2 E AGRP foram regulados positivamente. Parece que as alterações no mRNA estão contribuindo para as alterações fenotípicas no diabetes tipo 2, resultando em alterações fenotípicas associadas à transformação maligna. Tomando esses genes para realizar uma análise de sobrevivência, encontramos apenas os genes IGF1, USP2 e ARNTL2 associados à sobrevida. Enquanto a regulação negativa de IGF1 e USP2 teve um impacto negativo, a regulação positiva de ARNTL2 foi associada a uma pior sobrevida em amostras de câncer BLCA e BRCA. **Conclusão:** Essas moléculas biológicas não apenas representam a associação de diabetes tipo 2 e biomarcadores de ritmo circadiano com câncer de mama, bexiga, fígado, cólon e reto, mas também têm potencial significativo para serem consideradas como biomarcadores em nível de sistema que podem ser usados para triagem ou terapêutica finalidades.

Palavras-chave: Genes do relógio. IGF1. USP2. Síndrome metabólica. Hipotálamo. Córtex. Câncer.

ABSTRACT

Introduction: Tumorigenesis is affected by clock genes. Changes in the expression of clock genes can increase cancer susceptibility through the effects on biological mechanisms that regulate DNA damage and repair, energy metabolism, cell growth and death in neoplastic tissues **Objective:** to analyze the association of circadian rhythm, type 2 diabetes and cancer. **Methodology:** The study is a meta-analysis performed on type 2 diabetes, genes related to circadian rhythm and transcriptome data associated with breast, bladder, liver, pancreas, colon and rectum cancer using the integration of gene expression profiles with biomolecular in genome scale networks in diabetes samples, the databases searched were Pubmed and TCGA. The descriptors circadian rhythm, type 2 diabetes and cancer in English were used with Boolean operators *and* or *or*. **Results:** several common genes deregulate in diabetes mellitus and cancer. KLF10, NTKR3, IGF1, USP2, EZH2 were both down-regulated in samples of type 2 diabetes and cancer, while ARNTL2 AND AGRP were up-regulated. It appears that changes in mRNA are contributing to phenotypic changes in type 2 diabetes, resulting in phenotypic changes associated with malignant transformation. Taking these genes to perform a survival analysis, we found only the IGF1, USP2 and ARNTL2 genes associated with patient results. While negative regulation of IGF1 and USP2 had a negative impact, positive regulation of ARNTL2 was associated with poor survival in BLCA and BRCA cancer samples. **Conclusion:** These biological molecules not only represent the association of type 2 diabetes and circadian rhythm biomarkers with breast, bladder, liver, colon and rectum cancer, but also have significant potential to be considered as system-level biomarkers that can be used for screening or therapeutic purposes.

Keywords: Clock genes. IGF1. USP2. Metabolic syndrome. Hypothalamus. Cortex. Cancer.

LISTA DE ILUSTRAÇÕES

Figura 1 – Resumo dos bancos de dados.	24
---	----

LISTA DE SILGAS

ACS	American Cancer Society
ADA	American Diabetes Association
APC	Célula Apresentadora De Antígeno
ARNTL2	Aryl Hydrocarbon Receptor Nuclear Translocator Like 2
ATP	Adenosina Trifosfato
BLCA	Câncer Da Bexiga Urotelial
BRCA	Carcinoma Invasivo da Mama
CCG	Cuidados e Controles Gerais
CCR	Câncer Colorretal
COAD	Adenocarcinoma de Cólon
DEGs	Genes Diferencialmente Expressos
DNA	Ácido Desoxirribonucleico
EGR-1	Resposta de Crescimento Inicial 1
GLUT-4	Transportador de Glicose 4
GO	Ontologia Genética
HDL	Lipoproteína de Alta Densidade
IDF	Federação Internacional de Diabetes
IGF-1	Fator de Crescimento Semelhante a Insulina tipo 1
IL-6	Interleucina 6
IL-1 β	Interleucina 1 Beta
KEGG	Enciclopédia de Genes e Genomas de Kyoto
LIHC	Carcinoma Hepatocelular do Fígado
NCBI	National Center for Biotechnology Information
NF- κ β	Fator Nuclear Kappa β
PAAD	Adenocarcinoma do Pâncreas
PANTHER	Análise de Proteínas por Relações Evolutivas
PI3K	Fosfatidilinositol 3-Quinase
PTEN	Phosphatase and Tensin Homologue
READ	Adenocarcinoma do Reto
RNA	Ácido Ribonucleico
STK11	Serine/Threonine Kinase 1

TCGA	The Cancer Genome Atlas Program
TIMER	Tumor Immune Estimation Resource
TNF- α	Fator de Necrose Tumoral Alfa

SUMÁRIO

1 INTRODUÇÃO	12
2 OBJETIVOS	14
2.1 Objetivo Geral	14
2.2 Objetivos Específicos	14
3 REVISÃO DE LITERATURA	15
4 METODOLOGIA	23
4.1 Critérios de coleta e inclusão de estudos	23
4.2 Dados de microarray e processamento de dados	24
4.3 Lista de genes	25
4.4 Análise funcional e de enriquecimento de vias	25
4.5 Dados de RNA-seq e dados clínicos do TCGA	25
4.6 Análises de expressão de câncer	26
5 PRODUTOS	27
5.1 Produto 1- Artigo: Correlation between circadian rhythm related genes, type 2 diabetes, and cancer: insights from metanalysis of transcriptomics data	28
5.2 Produto 2 - Patente: Painel genético para diagnóstico e prognóstico do câncer de mama	78
6 CONCLUSÕES.....	79
REFERÊNCIAS	80
ANEXOS	86
ANEXO A – Regras para publicação no periódico	86

1 INTRODUÇÃO

Relógios biológicos são sistemas intrínsecos adaptados, que permitem aos organismos anteciparem as mudanças no ambiente ao seu redor, como por exemplo, a disponibilidade de comida e a predação e, com isso, permitem que eles adaptem seu comportamento e fisiologia às diferentes fases do dia, coordenando esses processos em ciclos de 24 horas (ZEE *et al.*, 2013).

A nível molecular, os ritmos biológicos são mantidos por uma maquinaria composta, fundamentalmente, por um conjunto de genes, os chamados genes relógio, que apresentam uma alça de retroalimentação e regulam o padrão circadiano de transcrição e tradução deles mesmos e de muitos genes controlados por eles, os chamados genes controlados pelo relógio (KENNAWAY *et al.*, 2006; BURDELAK *et al.*, 2013).

A influência externa e interna de diversos fatores como a intensidade e a duração do tempo de luz no ambiente, o estresse e as condições de saúde também são capazes de alterar os padrões rítmicos, como de atividade e repouso. Variações fisiológicas ao longo do dia podem ser observadas durante o ciclo regular, como alterações na atividade física e mental, na função cardiovascular e regulação de temperatura corporal. Também os parâmetros do sistema imunológico, como número de leucócitos, função, proliferação e produção de citocinas apresentam uma marcada variação circadiana (ZEE *et al.*, 2013; ZHU *et al.*, 2012; BERGER, 2008; KENNAWAY *et al.*, 2006).

A maquinaria molecular de transcrição circadiana não está apenas relacionada com a expressão dos genes relógio, eles estão envolvidos em diversas funções no organismo, como por exemplo, a secreção de hormônios, o envelhecimento, o ciclo celular, a resposta ao dano no DNA, dentre outros (RUTTER *et al.*, 2002; MAZZOCOLI *et al.*, 2012; BOZEK *et al.*, 2009). A desregulação do ritmo circadiano tem sido relacionada com o surgimento de diferentes patologias, como transtornos de humor, desordens metabólicas e também o câncer (MILLER *et al.*, 2007).

A tumorigênese é afetada pelos genes do relógio. Alterações da expressão dos genes do relógio podem aumentar a susceptibilidade ao câncer através dos efeitos nos mecanismos biológicos que regulam o dano e reparo ao DNA, o metabolismo energético, crescimento e morte celular em tecidos neoplásicos (NIRVANI *et al.*, 2018; GERY; KOEFFLER, 2010).

Além da relação entre a dessincronização e a maior incidência de alguns tipos de câncer, o ritmo circadiano também atua na regulação do metabolismo pelos genes do ciclo circadiano e afeta diferentes processos metabólicos, como o metabolismo da glicose, colesterol e função renal, pois os níveis dos hormônios metabólicos glucagon, insulina, grelina, leptina e

corticosterona oscilam de acordo com o ciclo circadiano (SINHA *et al.*, 1996; ECKEL-MAHAN; SASSONE-CORSI, 2009; SAHAR; SASSONE-CORSI, 2012). As consequências da desregulação desses genes a longo prazo podem causar síndrome metabólica e obesidade (TUREK *et al.*, 2005; MARCHEVA *et al.*, 2010; SASSONE-CORSI, 2012).

Existe uma forte associação entre obesidade, diabetes e câncer. Em 2010, a *American Diabetes Association* (ADA) e a *American Cancer Society* (ACS) publicaram um documento que afirma que o diabetes aumenta o risco de câncer de fígado, pâncreas, endométrio, cólon e reto, mama e bexiga (GIOVANNUCCI *et al.* 2010). Diabetes *mellitus* pode influenciar no surgimento de câncer de três formas principais: hiperinsulinemia, hiperglicemia ou inflamação crônica e desregulação dos hormônios sexuais (CALIMLIOGLU *et al.*, 2015; GIOVANNUCCI *et al.*, 2010). Cabe ressaltar que existem inúmeros fatores de riscos comuns entre diabetes mellitus e câncer como: idade, atividade física, obesidade, dieta, tabagismo e etilismo (GIOVANNUCCI *et al.*, 2010).

CALIMLIOGLU em seu estudo demonstrou a associação entre diabetes mellitus tipo 2 e câncer de pulmão, pâncreas, próstata e colorretal (CCR), demonstrando que as proteínas APC, EGFR, KPCA, MDM2, MK01, MK08, MYC, P53, TF65, TNR6, P85A 15 e SMAD3 estão associadas a mais de um tipo de câncer, as proteínas são oriundas de proto-oncogenes e genes supressores de tumor que, quando estão mutados, levam ao desenvolvimento do câncer (CALIMLIOGLU *et al.*, 2015).

Apesar da interação entre ritmos circadianos e câncer ser bastante descrita na literatura, pouco se sabe sobre genes envolvidos com o desenvolvimento de tumores que possam ser modulados pelo sistema de temporização circadiano, assim como se existe a associação entre o surgimento de câncer e diabetes relacionados a alteração do ritmo circadiano e dos genes do relógio envolvidos no processo. No presente estudo, buscou-se os elementos de ligação entre alteração do ritmo circadiano - câncer – diabetes.

2 OBJETIVOS

2.1 Objetivo geral

- Avaliar a associação do ritmo circadiano, diabetes tipo 2 e câncer utilizando ferramentas da bioinformática

2.2 Objetivos específicos

- Comparar a expressão diferencial de genes em diferentes amostras teciduais de indivíduos com e sem diabetes tipo 2;
- Diferenciar a expressão gênica em modelos animais para distúrbios do ritmo circadiano;
- Analisar a expressão gênica em tecidos de indivíduos sem câncer e em tecidos com tumores de mama, bexiga, reto, cólon, fígado e pâncreas;
- Associar a expressão diferencial de genes nas diferentes amostras de modelo animal de ritmo circadiano, diabetes tipo 2 e câncer;
- Analisar a sobrevida dos pacientes com os diferentes tipos de câncer, considerando o perfil de expressão gênica e vias metabólicas alteradas;

3 REVISÃO DE LITERATURA

Diabetes *Mellitus*

O Diabetes *mellitus* é uma doença crônica, autoimune, caracterizada por alterações na secreção e/ou atuação da insulina, com consequente hiperglicemia crônica, a qual é responsável pelas manifestações clínicas de polidipsia, poliúria e emagrecimento de forma involuntária (CALIMLIOGLU *et al.*, 2015; DEEPHI *et al.*, 2017). Outros sintomas que levantam a suspeita clínica são: fadiga, fraqueza, letargia, prurido cutâneo e vulvar, balanopostite e infecções de repetição. Algumas vezes o diagnóstico é feito a partir de complicações crônicas como neuropatia, retinopatia ou doença cardiovascular aterosclerótica (BRASIL, 2006; ADA, 2017)

De acordo com a Federação Internacional de Diabetes, (IDF), 1 a cada 11 adultos possuía diabetes em 2019, o equivalente a 423 milhões de pessoas (FEDERAÇÃO INTERNACIONAL DE DIABETES, 2019). No Brasil, há 12,5 milhões de pessoas com diagnóstico de diabetes, ocupando o 4º lugar entre os 10 países com maior número de indivíduos acometidos por ela; o 3º em número de crianças e adolescentes com diabetes tipo 1; e o 6º país do mundo em gastos com a doença (AMERICAN DIABETES ASSOCIATION, 2017). Entretanto, o Brasil não se enquadra entre os 10 países com maior investimento médio por indivíduo com diabetes (*Ibid.*).

As estimativas de mortalidade por diabetes e suas complicações a colocam entre as principais causas de morte por doença crônica no mundo, juntamente com doenças cardíacas isquêmicas e doenças cerebrovasculares (ZIMMET *et al.*, 2016). Em 2019, foi estimado um total de 4,2 milhões de mortes por diabetes, o equivalente a uma morte a cada oito segundos (FEDERAÇÃO INTERNACIONAL DE DIABETES, 2019). Em Alagoas, o diabetes mellitus representa a quarta maior causa de internações por condições sensíveis à atenção primária e a terceira causa de óbitos totalizando 13.103 no período de 2007 a 2016 (SESAU, 2017).

A depender de sua patogenia, é classificado em diabetes tipo 1, tipo 2, gestacional ou de outras causas específicas, sendo o diabetes tipo 2 o mais prevalente (90-95% dos casos) (AMERICAN DIABETES ASSOCIATION, AMERICAN DIABETES ASSOCIATION, 2019), sendo comum em adultos mais velhos. No entanto, em resposta às taxas crescentes de obesidade e sedentarismo, a incidência entre crianças e adolescentes está em crescente aumento (*Ibid.*).

Indivíduos com diabetes tipo 2 apresentam produção deficiente de insulina e resistência periférica à insulina concomitantemente, que estão associados a processo inflamatório crônico e estresse oxidativo às células β pancreáticas, produtoras de insulina, e aos tecidos que

respondem à ação do hormônio (DHARMALINGAM; MARCUS, 2019). A hiperglicemia é associada ao estresse oxidativo, o qual é caracterizado por um desequilíbrio na geração de radicais livres (espécies reativas de oxigênio-ROS- e espécies reativas de nitrogênio-RNS-) e sua neutralização pelos mecanismos anti-oxidantes, o aumento de ROS E RNS acarreta destruição das ilhotas pancreáticas por apoptose e conseqüentemente leve à resistência à insulina (*Ibid.*). A insulina tem atividade anti-inflamatória: suprime a transcrição de fatores pró-inflamatórios como o fator nuclear kappa β (NF- $\kappa\beta$), resposta de crescimento inicial 1 (EGR-1) e proteína ativadora 1 (AP-1) e seus genes correspondentes que medeiam a inflamação, porém, a resistência insulínica causa a ativação dessas transcrições levando à inflamação (*Ibid.*)

O desenvolvimento da resistência periférica à insulina relaciona-se à ação de mediadores pró-inflamatórios, tais como interleucina 1 beta (IL-1 β), interleucina 6 (IL-6), fator de necrose tumoral alfa (TNF- α) (AKASH; REHMAN; LIAQAT, 2017; DHARMALINGAM; MARCUS, 2019). Níveis elevados de TNF- α reduzem a expressão gênica do transportador de glicose 4 (GLUT-4) responsável pelo transporte da glicose para os adipócitos e células musculares esqueléticas e cardíacas - e induzem a fosforilação do substrato-1 do receptor de insulina (IRS-1), inativando-o e reduzindo a resposta fisiológica dos tecidos à insulina (AKASH; REHMAN; LIAQAT, 2017). Devido à inibição da captação da glicose e da ação da insulina, não há estímulo para produção de adenosina trifosfato (ATP) a partir da glicose, para glicogênese e para captação de aminoácidos e produção de proteínas nos tecidos musculares esquelético e cardíaco e para a lipogênese nos adipócitos. Além disso, a insulina torna-se incapaz de inibir a lipólise nos adipócitos e produção de glicose pelo fígado. Todos esses efeitos levam à hiperglicemia e ao desenvolvimento do diabetes (PETERSEN; SHULMAN, 2018). De modo que, os níveis elevados de glicose no sangue alteram vias metabólicas teciduais e provocam estresse oxidativo. No pâncreas endócrino, o acúmulo das espécies reativas de oxigênio altera o microambiente celular, acarretando a destruição das células beta e na produção deficiente de insulina, corroborando para maior elevação dos níveis sanguíneos de glicose e para a progressão do diabetes (DHARMALINGAM; MARCUS, 2019)

Tanto o processo inflamatório quanto o estresse oxidativo parecem ser desencadeados por fatores genéticos e epigenéticos, ainda não bem compreendidos, e por fatores de risco modificáveis, sendo a obesidade central o principal (AMERICAN DIABETES ASSOCIATION, 2019; DEEPHI, 2019), fator esse que pode estar relacionando tanto ao surgimento de neoplasias como pior sobrevida naqueles pacientes que a apresentam (GIOVANNUCCI *et al.*, 2010).

Diabetes *mellitus* e Câncer

Diabetes *mellitus* pode influenciar no surgimento de câncer de três formas principais: hiperinsulinemia, hiperglicemia ou inflamação crônica e desregulação dos hormônios sexuais (CALIMLIOGLU *et al.*, 2015; GIOVANNUCCI *et al.*, 2010). Muitas células neoplásicas expressam receptores de insulina e receptores de fator de crescimento semelhante à insulina tipo 1 (IGF-1), a hiperinsulinemia leva ao aumento da biodisponibilidade de IGF-1 por meio da diminuição dos níveis de suas proteínas de ligação, os receptores de IGF-1 são expressos em quase todos os tecidos do corpo e ativam vias mitogênicas na proliferação celular (GIOVANNUCCI *et al.*, 2010; ESPOSITO *et al.*, 2012). Por sua vez, os receptores de insulina, em particular, sua isoforma A podem estimular a mitogênese, mesmo em células deficientes de receptores de IGF-1, assim como é capaz de estimular a proliferação e metástase de células neoplásicas (GIOVANNUCCI *et al.*, 2010; COHEN; LEHOITH, 2012). A hiperglicemia também permite que o IGF-1 estimule a proliferação da célula do músculo liso vascular que está associado a fisiopatologia da aterosclerose assim como está presente no câncer (GIOVANNUCCI *et al.*, 2010), leva, ainda, à redução da síntese hepática e redução no sangue dos níveis de globulinas de ligação dos hormônios sexuais, acarretando aumento da biodisponibilidade do estrogênio em homens e mulheres, o aumento de estrogênio nas mulheres pós-menopausadas aumenta o risco de câncer de endométrio e de mama (GIOVANNUCCI *et al.*, 2010).

Existe uma forte associação entre obesidade, diabetes e câncer. Em 2010, a *American Diabetes Association* (ADA) e a *American Cancer Society* (ACS) publicaram um documento que afirma que o diabetes aumenta o risco de câncer de fígado, pâncreas, endométrio, cólon e reto, mama e bexiga (GIOVANNUCCI *et al.*, 2010). Cabe ressaltar que existem inúmeros fatores de riscos comuns entre diabetes mellitus e câncer como: idade, atividade física, obesidade, dieta, tabagismo e etilismo (GIOVANNUCCI *et al.*, 2010).

CALIMLIOGLU em seu estudo demonstrou a associação entre diabetes mellitus tipo 2 e câncer de pulmão, pâncreas, próstata e colorretal (CCR), demonstrando que as proteínas APC, EGFR, KPCA, MDM2, MK01, MK08, MYC, P53, TF65, TNR6, P85A e SMAD3 estão associadas a mais de um tipo de câncer, as proteínas são oriundas de proto-oncogenes e genes supressores de tumor que, quando estão mutados, levam ao desenvolvimento do câncer (CALIMLIOGLU *et al.*, 2015).

Fatores relacionados ao diabetes como a doença hepática não gordurosa, a qual se manifesta com esteatose e cirrose podem aumentar a suscetibilidade ao câncer hepático (GIOVANNUCCI *et al.*, 2010; BHATT; SIMTH, 2015). Em relação ao câncer de pâncreas, o mesmo pode ser a causa do metabolismo anormal da glicose, porém uma associação positiva foi encontrada quando o diagnóstico de diabetes mellitus antecede o câncer em 5 anos, diminuindo as chances da causa do diabetes mellitus ser o próprio câncer, provavelmente, pela associação entre a presença do diabetes e o surgimento de câncer pelos mecanismo de hiperinsulinemia, hiperglicemia ou inflamação crônica e desregulação dos hormônios sexuais (CALIMLIOGLU *et al.*, 2015; GIOVANNUCCI *et al.*, 2010).

Obesidade é um fator de confusão com relação a associação entre diabetes mellitus e o câncer de mama, já que ambas estão associadas à resistência periférica à insulina, o aumento dos níveis de insulina e de IGF-1 levam ao aumento dos níveis de estrogênio circulante pela redução das proteínas de ligação dos hormônios sexuais (estrógeno e andrógenos) ambos associados ao câncer de mama (AMERICAN DIABETES ASSOCIATION, 2017; DANTAS *et al.*, 2009; BUONO *et al.*, 2017).

HARDEFELDT *et al.* (2012,) em sua metanálise demonstraram um aumento de 20% no risco de câncer de mama em mulheres com diabetes mellitus e de 29% em homens (*Ibid.*). Por sua vez, BUONO demonstrou que pacientes que tinham a associação de obesidade, diabetes mellitus e câncer de mama apresentavam menores taxas de sobrevida livre de doença, independentemente do tamanho e subtipo do tumor, idade e/ou tratamento realizado, destacando-se, assim, o diabetes como um fator de mau prognóstico de forma isolada (BUONO *et al.*, 2017).

Mutações nos genes BRCA 1 e 2 estão relacionados com o câncer de mama hereditário, mulheres com mutações no BRCA 1 apresentam 87% de chance de desenvolver câncer e 85% quando a mutação é em BRCA 2 (HARDEFELDT *et al.*, 2012). Outros genes como p53, PTEN, STK11/LKB1, MLH1 e MLH2 também podem ter associação com síndromes hereditárias e seu risco aumentado para câncer de mama (LOFRANO *et al.*, 2009).

O gene PTEN foi descrito com papéis tanto no crescimento celular quanto na sinalização metabólica. Ele atua como gene supressor de tumor, principalmente devido à sua atividade de fosfatase lipídica que regula negativamente a via de sinalização da fosfatidilinositol 3-quinase (PI3K) -AKT que funciona como um mediador da maioria dos receptores de tirosina quinases (WANG *et al.*, 2014), ele também foi implicado no diabetes tipo 2, pois a via PI3K-AKT desempenha papel na sinalização de insulina (PAL *et al.*, 2012). Mutações germinativas do

PTEN predispõem ao processo de desenvolvimento neoplásico, assim como ao desenvolvimento de obesidade (PAL *et al.*, 2012).

O mecanismo biológico entre diabetes mellitus e CCR, não está claramente definido, havendo a possibilidade de estar relacionado aos fatores de risco comuns associados à obesidade e inflamação, assim como hiperinsulinemia e hiperglicemia (ZHU *et al.*, 2017). Del Puerto-Nevado *et al.* (2017) demonstraram a expressão de alguns genes no diabetes mellitus que têm relação com câncer colorretal: APC; KRAS; p53; MSH2; MSH6 estão aumentados, assim como o aumento de STK11 que está associada à síndrome de Peutz-Jegher (*Ibid.*).

Ritmo circadiano

Relógios biológicos são sistemas intrínsecos adaptados, que permitem aos organismos anteciparem as mudanças no ambiente ao seu redor, como por exemplo, a disponibilidade de comida e a predação e, com isso, permitem que eles adaptem seu comportamento e fisiologia às diferentes fases do dia, coordenando esses processos em ciclos de 24 horas (ZEE *et al.*, 2013). Essa sincronização aos ciclos ambientais provoca a sincronização interna dos eventos fisiológicos circadianos. Como consequência, os organismos conseguem antecipar os eventos fisiológicos, economizando energia e otimizando as reações. Essas observações evidenciam a importância de manter a ordem temporal interna, com as relações de fase bem estabelecidas entre as variáveis fisiológicas (*Ibid.*).

O termo “ritmo circadiano” (do Latim *circa diem* que significa “cerca de um dia”) foi criado para descrever oscilações endógenas em organismos, que foram assim classificadas por conter um período aproximado ao da rotação diária do planeta Terra (ZEE *et al.*, 2013; ZHU *et al.*, 2012). Uma das características dos relógios circadianos é a capacidade de serem sincronizados por estímulos externos, mantendo, entretanto, as oscilações mesmo na ausência desses estímulos, ou seja, são autossustentáveis (ZEE *et al.*, 2013; ZHU *et al.*, 2012; KENNAWAY *et al.*, 2006).

Um grande número de processos biológicos é regulado pelo relógio circadiano, como por exemplo: comportamento alimentar, ciclos de sono-vigília, variação hormonal, temperatura corporal e metabolismo energético (ZEE *et al.*, 2013; KENNAWAY *et al.*, 2006). Contudo, a influência externa e interna de diversos fatores como a intensidade e a duração do tempo de luz no ambiente, o estresse e as condições de saúde também são capazes de alterar os padrões rítmicos, como de atividade e repouso. Variações fisiológicas ao longo do dia podem ser observadas durante o ciclo regular, como alterações na atividade física e mental, na função

cardiovascular e regulação de temperatura corporal. Também os parâmetros do sistema imunológico, como número de leucócitos, função, proliferação e produção de citocinas apresentam uma marcada variação circadiana (ZEE *et al.*, 2013; ZHU *et al.*, 2012; BERGER, 2008; KENNAWAY *et al.*, 2006).

A nível molecular, os ritmos biológicos são mantidos por uma maquinaria composta, fundamentalmente, por um conjunto de genes, os chamados genes relógio, que apresentam uma alça de retroalimentação e regulam o padrão circadiano de transcrição e tradução deles mesmos e de muitos genes controlados por eles, os chamados genes controlados pelo relógio (CCGs, do inglês *clock controlled genes*) (KENNAWAY *et al.*, 2006; BURDELAK *et al.*, 2013).

Ritmo Circadiano, Câncer e Síndrome metabólica

A maquinaria molecular de transcrição circadiana não está apenas relacionada com a expressão dos genes relógio, eles estão envolvidos em diversas funções no organismo, como por exemplo, a secreção de hormônios, o envelhecimento, o ciclo celular, a resposta ao dano no DNA, dentre outros (RUTTER *et al.*, 2002; MAZZOCCOLI *et al.*, 2012; BOZEK *et al.*, 2009). A desregulação do ritmo circadiano tem sido relacionada com o surgimento de diferentes patologias, como transtornos de humor, desordens metabólicas e também o câncer (MILLER *et al.*, 2007).

O relógio circadiano e o ciclo celular possuem semelhanças conceituais e moleculares, pois ambos são constituídos por processos que apresentam alças de regulação interligadas e apresentam sequências de transcrição, tradução, modificação e degradação de proteínas (MAZZOCCOLI *et al.*, 2012; LANDGRAF; SHOSTAK; OSTER, 2012; SOTÁK *et al.*, 2013). Existem interações entre esses dois ciclos e, quando há uma desregulação no ritmo circadiano, há uma alteração no ciclo celular, fazendo com que as células se proliferem desordenadamente.

Alterações da expressão dos genes do relógio podem aumentar a susceptibilidade ao câncer através dos efeitos nos mecanismos biológicos que regulam o dano e reparo ao ácido desoxirribonucléico (DNA), o metabolismo energético, crescimento e morte celular em tecidos neoplásicos (NIRVANI *et al.*, 2018; GERY; KOEFFLER, 2010). Genes que fazem parte do mecanismo de regulação do ciclo celular, como Myc, p53, Cyclin D1 e Wee1, já foram descritos por apresentarem alteração em sua expressão em pacientes com leucemias associadas à desregulação de genes do relógio (ZEE *et al.*, 2013; MAZZOCCOLI *et al.*, 2012; LANDGRAF; SHOSTAK; OSTER, 2012)

Além da relação entre a dessincronização e a maior incidência de alguns tipos de câncer, o ritmo circadiano também atua na regulação do metabolismo pelos genes do ciclo circadiano e afeta diferentes processos metabólicos, como o metabolismo da glicose, colesterol e função renal, pois os níveis dos hormônios metabólicos glucagon, insulina, grelina, leptina e corticosterona oscilam de acordo com o ciclo circadiano (SINHA *et al.*, 1996; ECKEL-MAHAN; SASSONE-CORSI, 2009; SAHAR; SASSONE-CORSI, 2012). As consequências da desregulação desses genes a longo prazo podem causar síndrome metabólica e obesidade (TUREK *et al.*, 2005; MARCHEVA *et al.*, 2010; SASSONE-CORSI, 2012).

A incidência de síndrome metabólica está aumentando no mundo ocidental e sua correlação com o câncer tem se tornado mais aparente (BRAUN *et al.*, 2011). A síndrome metabólica é uma combinação de condições patológicas que coexistem num mesmo indivíduo, incluindo hiperglicemia, hipertensão, hipertrigliceridemia, baixo nível da lipoproteína de alta densidade (HDL) e aumento da circunferência abdominal (ALBERTI *et al.*, 2009; BATTELLI *et al.*, 2019). Essa combinação de fatores predispõe à obesidade, ao aumento de doenças cardiovasculares, diabetes tipo 2 e vários estudos têm associado à prevalência de certos tipos de câncer (BITZUR *et al.*, 2016; BELLASTELLA, G. *et al.*, 2018). No estudo de Esposito (2012), nos homens, a síndrome metabólica foi associada com os cânceres de fígado, cólon e bexiga. Enquanto, que, nas mulheres, esse estudo revelou uma associação com cânceres endometrial, pancreático, mama pós-menopausa, retal e colorretal (ESPOSITO *et al.*, 2012).

A fisiopatologia da síndrome metabólica está relacionada principalmente com a capacidade do tecido adiposo secretar uma ampla variedade de mediadores bioativos que modulam várias cascatas de sinalização, os quais são chamados de adipocinas (OUCHI *et al.*, 2011; MENDONÇA *et al.*, 2015). Nos pacientes com síndrome metabólica, ocorre uma desregulação na produção de adipocitocinas, as quais podem desencadear um estado inflamatório crônico (BRAUN *et al.*, 2011; MENDONÇA *et al.*, 2015). A inflamação e seus mediadores aumentam o risco de desenvolver câncer de esôfago, mama, vesícula biliar, renal, pancreático, colorretal e gástrico (GRAI *et al.*, 2015; HRISTOVA, 2018).

Na obesidade, há um aumento dos ácidos graxos livres, citocinas inflamatórias no plasma, infiltração e ativação de macrófagos e decréscimo dos níveis de adiponectina, os quais podem contribuir para a resistência à insulina (BRAUN *et al.*, 2011). O aumento da biodisponibilidade da insulina causa o diabetes tipo 2, podendo ativar as vias de efeito mitogênico (Ras /Raf/ MAPK ou PI3K /AKT/ mTOR), diminuir a apoptose e aumentar a síntese de proteínas (WONG

et al., 2010; BELLASTELLA *et al.*, 2018). A ativação dessas vias carcinogênicas predispõe ao aumento do risco de câncer (WONG *et al.*, 2010; BELLASTELLA *et al.*, 2018).

Pacientes obesos têm níveis elevados de leptina, que tem atividade mitogênica/anti-apoptótica, estimula a migração e invasão das células neoplásicas, pode aumentar a produção de citocinas pelos macrófagos e pode promover a neoangiogênese através da indução e ativação de fatores pro-angiogênicos (COHEN; LEROITH, 2012; LIGIBEL; STRICKLER, 2013) e possuem baixos níveis de adiponectina que tem atividade anti-mitótica/pro-apoptótica (LIGIBEL; STRICKLER, 2013).

Apesar da interação entre ritmos circadianos e câncer ser bastante descrita na literatura, pouco se sabe sobre genes envolvidos com o desenvolvimento de tumores que possam ser modulados pelo sistema de temporização circadiano, assim como se existe a associação entre o surgimento de câncer e diabetes relacionados a alteração do ritmo circadiano e dos genes do relógio envolvidos no processo.

4 METODOLOGIA

O estudo é uma metanálise, onde os bancos de dados pesquisados foram o Pubmed e *The Cancer Genome Atlas Program* (TCGA). Foram utilizados os descritores ritmo circadiano, diabetes tipo 2 e câncer em inglês com operadores booleanos *and* ou *or*.

4.1 Critérios de coleta e inclusão de estudos

Foi pesquisado o banco de dados GEO (<https://www.ncbi.nlm.nih.gov/geo/>) para estudos disponíveis publicados. Após uma revisão sistemática, 6 estudos de GSE foram encontrados. Os critérios de inclusão para os estudos foram os seguintes:

- (1) amostras diagnosticadas com diabetes mellitus tipo 2 e amostras normais
- (2) experimentos que envolviam ritmo circadiano e / ou análise do sono
- (3) perfil de expressão gênica de mRNA (ácido ribonucléico).

Seis perfis de diabetes de expressão gênica tipo 2 (GSE56931, GSE20966, GSE25724, GSE26168, GSE23343 e GSE29221) foram baixados do banco de dados GEO para análise, já para avaliação de privação de sono, apenas o GSE6514 foi baixado

Os perfis de expressão de genes humanos de pacientes diabéticos tipo 2 e não diabéticos de tecido enriquecido com células beta foram obtidos por microdissecção de captura a laser foram:

- GSE20966 (20 amostras / 7 mulheres e 13 homens)
- GSE25724 (ilhotas pancreáticas - 13 amostras / 6 mulheres e 7 homens)
- GSE26168 (sangue - 24 amostras masculinas)
- GSE23343 (fígado - 17 amostras / 7 mulheres e 10 homens)
- GSE29221 (músculo esquelético - 24 amostras masculinas)

As coletas de sangue a cada 4 horas durante um estudo de 3 dias: linha de base normal de 24 horas, 38 horas de vigília contínua e sono de recuperação subsequente, para um total de 19

pontos de tempo por sujeito, com cada avaliação de teste de vigilância psicomotora de 2 horas quando acordado (GSE56931).

Experimentos de privação de sono GSE6514 foram realizados em camundongos machos amostras C57 / BL6 com, aproximadamente, 10 semanas de idade com \pm 1 semana de diferença. Os animais foram alojados em um ciclo claro/escuro de 12:12 h com água disponível *ad libitum*, foram submetidos a 14 dias de aclimação, durante os quais foi estabelecido um padrão alimentar noturno. Os camundongos foram sacrificados após 3, 6, 9 e 12 horas de privação total de sono. A privação foi iniciada com a luz acesa e realizada por meio de um manuseio delicado. As amostras de GSE82113 foram analisadas em condições normais de privação de sono e condições de tempo de sono anormais para avaliar a robustez do preditor. Amostras de sangue cobrindo pelo menos um ciclo circadiano para medir a abundância de mRNA (ácido ribonucleico) e medir o ritmo da melatonina. Também foram realizadas análises em perfis de tecidos periféricos. GSE4239 foi usado para determinar genes regulados pelo relógio na glândula adrenal. Animais *Per2Brdm1 / Cry1- / -* foram usados para análise de expressão. Os animais foram conduzidos a um ciclo de 12 horas de luz: 12 horas de escuridão por duas semanas e depois liberados em escuridão constante. A alimentação restrita impacta o relógio circadiano hepático de *Cry1*, camundongos duplo *Knockout Cry2* sem um relógio circadiano foi realizada usando o perfil GSE13062. Da mesma forma, o tecido do fígado de tipo selvagem, mutante de *Clock* e C57BL / 6 deficiente em *Cry* camundongos machos de 8 a 10 semanas de idade foi examinado no perfil GSE454. Os camundongos foram arrastados sob 12 h de luz branca e 12 h de escuridão por 14 dias. O perfil GSE6904 mostrou que os dados de camundongos foram expostos a partir de 1 h após as luzes apagadas a um pulso de luz de 30 minutos. No final do pulso de luz, os ratos foram sacrificados e os cérebros extraídos. As células do núcleo supraquiasmático foram extraídas usando microscopia de captura a laser e a expressão gênica foi quantificada usando *Affymetrix microarrays*.

4.2 Dados de microarray e processamento de dados

GEO2R foi aplicado para rastrear mRNAs diferencialmente expressos entre diabetes mellitus tipo 2 e amostras de tecido normal.

GEO2R (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>) é uma ferramenta da web interativa para comparar dois grupos de dados que podem analisar qualquer série GEO. Os valores de p

ajustados usando o método de de Benjamini e Hochberg padrão foram aplicados para corrigir a ocorrência de resultados falso-positivos.

4.3 Lista de genes

Entrez Gene da NCBI (www.ncbi.nlm.nih.gov/gene/) e GeneCards (<https://www.genecards.org/>) foram usados como identificadores dos genes relacionados ao ritmo circadiano. A lista de genes e DEGs downregulated / upregulated dos perfis de expressão gênica foram combinados e identificados com um Diagrama de Venn 2.1.0 (<http://bioinfo.gp.cnb.csic.es/tools/venny/index.html>).

4.4 Análise funcional e de enriquecimento de vias

A análise da ontologia genética (GO) dos processos biológicos relevantes, componentes celulares e funções moleculares foi realizada usando o programa Análise de Proteínas por Relações Evolutivas (PANTHER, www.pantherdb.org), um banco de dados que reúne famílias de proteínas, funções e vias. Os termos GO atribuídos às moléculas identificadas foram classificados de acordo com a sua função (BASTOS *et al.*, 2011). A Enciclopédia de Genes e Genomas de Kyoto (KEGG) é um banco de dados integrado para interpretação biológica de sequências de genoma e outros dados de alto rendimento (KANEHISA *et al.*, 2016). As análises do KEGG estavam disponíveis no banco de dados DAVID (<https://david.ncifcrf.gov/>), um recurso de dados composto por uma base de conhecimento de biologia integrada e ferramentas de análise para extrair informações biológicas significativas de grandes quantidades de genes e coleções de proteínas. As análises KEGG foram realizadas usando o banco de dados DAVID para identificar DEGs (genes expressos diferencialmente). Um valor de $p < 0,05$ foi estabelecido como o critério de corte (HUANG *et al.*, 2009).

4.5 Dados de RNA-seq e dados clínicos do TCGA


Foi utilizado o TCGAblinks em R/Bioconductor (<http://bioconductor.org/packages/release/bioc/html/TCGAblinks.html>) (COLAPRICO *et al.*, 2016) e o TCGAblinksGUI (SILVA *et al.*, 2018) para baixar dados genômicos e clínicos de tecidos normais e de tumores sólidos para seis tipos de câncer do TCGA. Os tipos de câncer foram: câncer da bexiga urotelial (BLCA), carcinoma invasivo da mama (BRCA), adenocarcinoma do

cólon (COAD), carcinoma hepatocelular do fígado (LIHC), adenocarcinoma do pâncreas (PAAD) e adenocarcinoma do reto (READ). Foram recuperados dados de nível para a expressão de mRNA e miRNA (ILLUMINA HISEQ, 2000).

4.6 Análises de expressão de câncer

Utilizamos o servidor da *web Tumor Immune Estimation Resource* (TIMER) (<https://cistrome.shinyapps.io/timer/>), uma ferramenta analítica abrangente que reanalisou dados do TCGA, para detectar a expressão gênica em vários tipos de câncer (LI *et al.*, 2017). Os perfis de expressão de BLCA, BRCA, COAD, LIHC, PAAD e READ para amostras normais comparadas com as neoplásicas foram obtidos usando a opção TIMER diff.exp (<https://cistrome.shinyapps.io/timer/>). A análise de sobrevida dos dados do TCGA foi realizada utilizando o módulo *Survival* do *Tumor Immune Estimation Resources* (TIMER). Gráficos de Kaplan-Meier foram desenhados para explorar a associação entre o resultado clínico e a expressão gênica e para visualizar as diferenças de sobrevida. Dados de proteína baseados em imagens de imunohistoquímica para amostras normais e de câncer estão disponíveis no Atlas de Proteínas humanas (<https://www.proteinatlas.org/>).

Figura 1 - Resumo dos bancos de dados utilizados e as finalidades para qual foram utilizados



Fonte: elaborado pelos autores

5 PRODUTOS

1. Correlation between circadian rhythm related genes, type 2 diabetes, and cancer: insights from metanalysis of transcriptomics data, segundo as normas da Molecular and Cellular Endocrinology
2. Patente: Privilégio de Inovação. Número do registro: BR10202002668, título: "Painel genético para diagnóstico e prognóstico do câncer de mama", Instituição de registro: INPI - Instituto Nacional da Propriedade Industrial. Depósito: 24/12/2020

5.1 PRODUTO 1

Correlation between circadian rhythm related genes, type 2 diabetes, and cancer: insights from metanalysis of transcriptomics data. Publicado no periódico Molecular and Cellular Endocrinology

Correlation between circadian rhythm related genes, type 2 diabetes, and cancer: insights from metanalysis of transcriptomics data

Thaysa Kelly Barbosa Vieira^{1#}, Myra Jurema da Rocha Leão^{1#}, Luciana Xavier Pereira¹, Laryssa Cristina Alves da Silva¹, Bruno Batista Pereira da Paz¹, Ricardo Jansen Santos Ferreira¹, Christiane Cavalcante Feitoza¹, Ana Kelly Fernandes Duarte¹, Amanda Karine Barros Ferreira Rodrigues¹, Aline Cavalcanti de Queiroz¹, Karol Fireman de Farias¹, Bruna Del Vechio Koike^{2*}, Carolinne de Sales Marques^{1*}, Carlos Alberto de Carvalho Fraga^{1*}

¹ Federal University of Alagoas, Campus Arapiraca. Av. Manoel Severino Barbosa, Bom Sucesso, Arapiraca, AL 57309-005, Brazil.

² Federal University of the São Francisco Valley, Petrolina. Av. José de Sá Maniçoba, S/N - Centro, Petrolina - PE, 56304-917, Brazil.

Both authors contributed equally to this work

* Corresponding authors Carlos Alberto de Carvalho Fraga, Carolinne de Sales Marques and Bruna Del Vechio Koike.

e-mail:carlos.fraga@arapiraca.ufal.br

ABSTRACT

Clock genes work as an auto-regulated transcription-translational loop of circadian genes that drives the circadian rhythms in each cell and they are essential to physiological requests. Since metabolism is a dynamic process, it involves several physiological variables that circadian cycling. The clock genes alterations can affect multiple systems concomitantly, because they constitute the promoter factors for relevant metabolic pathways. Considering the intertwined structure of signaling, regulatory, and metabolic processes within a cell, we employed a genome-scale biomolecular network. Accordingly, a meta-analysis of diabetic-associated transcriptomic datasets was performed, and the core information on differentially expressed genes (DEGs) was obtained by statistical analyses. In the current study, meta-analysis was performed on type 2 diabetes, circadian rhythm-related genes, and breast, bladder, liver, pancreas, colon and rectum cancer-associated transcriptome data using the integration of gene expression profiles with genome-scale biomolecular networks in diabetes samples. First, we detected downregulated and upregulated DEGs in mouse cortex and hypothalamus samples of mice with sleep deprivation. In summary, upregulated genes active genes associated with oxidative phosphorylation, cancer and diabetes, mainly in hypothalamus specimens. In cortex, we observed mainly downregulation of immune system. DEGs were combined with 214 circadian rhythm related genes to type 2 DM and cancer samples. We observed that several common genes deregulated in both diseases. *Klf10*, *Ntkr3*, *Igf1*, *Usp2*, *Ezh2* were both downregulated in type 2 DM and cancer samples, while *Arntl2* and *Agrp* were upregulated. It seems that the changes in mRNA are contributing to the phenotypic changes in type 2 DM, resulting in phenotypic changes associated with the malignant transformation. Taking those genes to perform a survival analysis, we found only *Igf1*, *Usp2* and *Arntl2* genes associated with patient outcomes. While *Igf1* and *Usp2* downregulation had a negative impact, *Arntl2* upregulation was associated with poor survival both in BLCA and BRCA cancer samples. Our data stimulate efforts in news studies to achieve the experimental and clinical validation about these biomolecules.

Key-words: clock genes; IGF1; USP2; metabolic syndrome; hypothalamus; cortex; cancer

INTRODUCTION

Tumorigenesis is affected by clock genes. Clock genes control gene expression and cell cycle being directly involved in the regulation of cell division (Gery et al., 2006; Reddy et al., 2005), cell proliferation or apoptosis (Hua et al., 2006; Rana et al., 2014), control of cell-cycle checkpoints (Ben-Shlomo, 2014; Borgs et al., 2009), and response to DNA damage (Fu et al., 2002; Gery et al., 2006). When these functions are altered, raise cancer development propensity (Gery and Koeffler, 2010).

Clock genes work as an auto-regulated transcription-translational loop of circadian genes that drives the circadian rhythms in each cell and they are essential to physiological requests (Dunlap, 1999; Lowrey and Takahashi, 2011). The circadian proteins are altered in tumor cells when compared to the adjacent normal cells in several tissues, such as breast tumors (Chen et al., 2005); endometrial carcinoma (Yeh et al., 2005); and lung cancer (Gery et al., 2006). Several clock genes may function as oncogenes, such as *Arntl2*, *Nr1d1*, and *Npas2*, while other clock genes may function as a tumor suppressors, such as *Pers*, *Cry3* and *Rors* (Ye et al., 2016). Once they control the cell cycle, the metabolism is also controlled by the internal temporal system. In this system, the central oscillator (the suprachiasmatic nucleus of hypothalamus) orchestrates the peripheral oscillators, which include systems, organs, tissues and cells.

Since metabolism is a dynamic process, it involves several physiological variables that circadian cycling. Clinical and experimental studies have demonstrated that clock genes expression are closely related to metabolic syndrome (Gómez-Abellán et al., 2008; Scott et al., 2008) and to an increased risk for cardiometabolic disorders (de Oliveira et al., 2019; Golombek et al., 2013; Karatsoreos et al., 2011). This increased risk includes alterations on the hepatic insulin pathway, indicative of hepatic insulin resistance (de Oliveira et al., 2019). The gene expression of pancreatic islet cells (Perelis et al., 2015; Saini et al., 2016) and rennin-angiotensin system (Herichova et al., 2014; Ohashi et al., 2017) are regulated by the core clock genes. The clock genes alterations can affect multiple systems concomitantly, since they constitute promoter factors for type 2 diabetes (Cao and Wang, 2017). We recently published biological molecules not only represent association of type 2 diabetes and breast, bladder, liver, pancreas, colon and rectum cancer but also have significant potential to be considered as systems-level biomarkers that may be used for screening or therapeutic purposes (Pereira et al., 2019); however, the link between them and clock genes altered expressions are still unknown.

The cellular metabolism relies on circadian control, both within normal or tumor cells, in this way, the circadian desynchronization can occur at molecular level and/or systemically. Individuals with shift work are prone to develop cancer and metabolic syndrome. The International Agency for Research on Cancer of the World Health Organization determined that shift work at night is the most disruptive for the circadian clock and, for this reason, increase the tendency to cancer development (Blair et al., 2010). It was classified as “probably carcinogenic to humans” (International Agency for Research on Cancer, 2019). All these data converge to the same point: the circadian disruption can lead to the metabolic disorders and cancer development. We, in the present study, are searching the cross-talk elements to close the circuit: chrono disruption – cancer – diabetes.

METHODS

Collection and inclusion criteria of studies

We searched the GEO database (<https://www.ncbi.nlm.nih.gov/geo/>) for publicly available studies. The inclusion criteria for studies were as follows: (1) samples diagnosed with type 2 DM and normal samples, (2) experiments that involve circadian rhythm and/or sleeping analysis and, (3) gene expression profiling of mRNA. After a systematic review, seven gene expression profiles (GSE56931, GSE20966, GSE25724, GSE26168, GSE23343, GSE29221 and GSE6514) were collected. GSE20966 (20 samples/ 7 female and 13 male) is a human gene expression profiles of beta-cell enriched tissue obtained by Laser Capture Microdissection from subjects with type 2 diabetes. GSE25724 (pancreatic islets – 13 samples/ 6 female and 7 male), GSE26168 (blood – 24 male samples), GSE23343 (liver – 17 samples/ 7 female and 10 male), GSE29221 (skeletal muscle – 24 male samples) are human expression data from type 2 diabetic and non-diabetic male and female patients.

Blood draws every 4 hours during a 3-day study: 24-hour normal baseline, 38 hours of continuous wakefulness and subsequent recovery sleep, for a total of 19 time-points per subject, with every 2-hr psychomotor vigilance test assessment when awake (GSE56931). GSE6514 sleep deprivation experiments were performed on male mice (C57/BL6), 10 weeks of age \pm 1 week. Animals were housed in a light/dark cycle of 12:12 h with water available *ad libitum*. Animals were subjected to 14 days of acclimatization during which a nighttime feeding pattern was established. Mice were euthanized following 3, 6, 9 and 12 h of total sleep deprivation. Deprivation was initiated at lights on and performed through gentle handling.

GSE82113 samples was analyzed under normal, sleep-deprivation and abnormal sleep-timing conditions to assess robustness of the predictor. Blood samples covering at least one circadian cycle to measure mRNA abundance and measuring melatonin rhythms. We also performed analysis in peripheral tissue profiles. GSE4239 was used to determine clock regulated genes in the adrenal gland. *Per2Brdm1/Cry1^{-/-}* animals was used for expression analysis. Animals were entrained to a 12 hr light:12 hr dark cycle for two weeks and after released into constant darkness. Restricted feeding impacts the hepatic circadian clock of *Cry1*, *Cry2* double KO mice lack a circadian clock was performed by using GSE13062 profile. Similarly, liver tissue of wildtype, Clock mutant and *Cry* deficient C57BL/6 8- to 10-week-old male mice was examined in GSE454 profile. Mice were entrained under 12 h of white light and 12 h of darkness for 14 days. GSE6904 profile showed data from mice were exposed starting at 1 hour after lights off to a 30-minute light pulse. At the end of the light pulse, mice were

ethanized and the brains extracted. Cells from the suprachiasmatic nucleus were extracted using laser capture microscopy and gene expression was quantified using Affymetrix microarrays.

Microarray data and Data processing

GEO2R was applied to screen differentially expressed mRNAs between type control and experimental tissue samples. GEO2R (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>) is an interactive web tool for comparing two groups of data that can analyze any GEO series. The p-values using Benjamin and Hochberg false discovery rate method by default were applied to correct the occurrence of false positive results.

Cancer expression analyses

Gene list collection, Functional and pathway enrichment analysis, RNA-seq and clinical information data from TCGA were performed as previously described (Pereira et al., 2019). We performed survival analysis using Tumor Immune Estimation Resource (TIMER) a web server (<https://cistrome.shinyapps.io/timer/>) (Li et al., 2017). Kaplan–Meier for BLCA, BRCA, COAD, LIHC, PAAD and READ expression profiles plots were drawn to explore the association between clinical outcome and gene expression. Immunohistochemistry protein data for normal and cancer samples were performed with the Human Protein Atlas (<https://www.proteinatlas.org/>).

RESULTS

Identification of differentially expressed genes, gene ontology enrichment and functional classification

In an attempt to characterize the molecular signaling events in temporal changes in gene expression during spontaneous sleep and extended wakefulness, we adopted a dataset of expression profiling of mRNA from GEO database. This dataset contains the total mRNA of animals euthanized at different times during the lights on period. The experiments address temporal changes in gene expression during spontaneous sleep and extended wakefulness in the mouse cerebral cortex, a neuronal target for processes that control sleep; and the hypothalamus, an important site of sleep regulatory processes. To identify the differentially expressed genes (DEGs), we applied the online tool GEO2R and found out upregulated and downregulated genes.

We performed a GO term enrichment and functional classification by DAVID to investigate the biological and functional roles of these DEGs. In cortex, we observed downregulation of cell adhesion molecules (CAMs) after 3h and 6h of sleep deprivation. Neuroactive ligand-receptor interaction pathway was downregulated after 9h and 12 h of sleep deprivation. Galactose metabolism pathway and Viral myocarditis, Asthma and, Allograft rejection pathways were upregulated after 6h and 12h, respectively. According to hypothalamus analysis, downregulation of Retinol metabolism and Complement and coagulation cascades pathways were observed after 3h and, neurotrophin signaling pathway, Pathways in cancer and signaling pathway were the top three pathways downregulated after 6h of sleep deprivation. Calcium signaling pathway was downregulated after 9h and, colorectal cancer and Melanogenesis pathways were found after 12h. Phosphatidylinositol signaling system and oxidative phosphorylation pathways were found active after 3h and 6h, respectively. Active pathways found after 9h of sleep deprivation were pathways in cancer, maturity onset diabetes of the young, intestinal immune network for IgA production and natural killer cell mediated cytotoxicity. Finally, PPAR signaling pathway and cytokine-cytokine receptor interaction were active after 12h of sleep deprivation.

To analyze the functional classification and to facilitate the high-throughput analysis of these DEGs, a protein classification analysis according to family and subfamily of the identified DEGs was performed by the PANTHER classification system. According to the study, after 3h, 6h, 9h and 12h of sleep deprivation in both hypothalamus and cortex samples, we identified that binding (GO:0005488), catalytic activity (GO:0003824) and molecular function regulator

(GO:0098772) are the top three abundant protein classes.

Data from hepatic tissue of *Cry1, 2* double knockout temporally restricted feeding mice showed Fatty acid biosynthesis and insulin signaling pathways were downregulated when compared to wildtype mice. Drug and linoleic acid metabolisms were upregulated (GSE13062). Downregulation of cell cycle, Pathways in cancer, axon guidance, and Wnt signaling was observed in clock mutant mice. *Cry* deficient showed downregulation of cell cycle and neuroactive ligand receptor, while Pathways in cancer was upregulated when compared to wild type mice (GSE454). Expression data from mice suprachiasmatic nucleus after 30 minutes light pulse (GSE6904) showed downregulation of ECM-receptor interaction and upregulation of Mapk signaling, Focal adhesion and Wnt signaling pathways (Supplementary Table 1-16).

Overview of the type 2 diabetes and cancer transcriptomic analysis

We previously characterized the molecular signaling events in the diabetes by using datasets containing the total mRNA of normal/diabetic pairs of pancreatic islets, blood and skeletal muscle tissues (Pereira et al., 2019). We applied the online tool GEO2R and found out upregulated and downregulated genes in isolated human pancreatic islets, liver, blood dataset, and skeletal muscle. By using Entrez Gene and KEGG pathway analysis, we identified 214 circadian rhythm-related genes. Venn diagram was performed to show the overlap between DEG genes identified from the meta-analysis and those from the circadian rhythm-related genes. In diabetic samples, abundant circadian rhythm expression variations were observed indicating that different gene expression patterns may exist in diabetic tissues (Figure 1).

We obtain the gene expression data of specimens across 6 cancer types from TCGA and preprocessed the data of each cancer type with standard methods. These cancer types include Bladder Urothelial Cancer (BLCA), breast invasive carcinoma (BRCA), Colon Adenocarcinoma (COAD), Liver Hepatocellular carcinoma (LIHC), Pancreas adenocarcinoma (PAAD) and Rectum Adenocarcinoma (READ). We conducted a systematic and integrative cancer analysis to explore cancer type-specific circadian rhythm subnetworks. Specifically, to construct a cancer network, we first determine DEGs by comparing expression level of tumors to normal samples. In tumors abundant circadian rhythm expression variations were observed indicating that different gene expression patterns may exist in cancer tissues. *Klf10* was downregulated in BLCA, BRCA, LIHC and READ; *Ntrk3* and *Igf1* were downregulated in BLCA, BRCA, COAD, LIHC and READ; Similarly, *Klf9* and *Usp2* downregulation were found in BLCA, BRCA, COAD and READ. *Ezh2*, *Cdk1*, *Top2a*, *Agrp*, *Aanat* and *Ren* were

upregulated in BLCA, BRCA, COAD and READ, while *Arntl2* was upregulated in BLCA, BRCA, COAD and READ. *Klf10* was also found to be downregulated in blood samples from type 2 diabetic patients. Similarly, *Ntrk3* and *Igf1* were downregulated in blood and skeletal samples and, skeletal and liver samples, respectively. *Usp2* was observed to be downregulated in blood samples. *Ezh2* was upregulated in blood samples, while *Arntl2* and *Agrp* was upregulated in skeletal muscle (Figure 1, Supplementary Table 17-19, respectively).

Survival analysis showed that *Igf1* and *Usp2* low expression was associated with poor survival in BLCA, LIHC, AND BRCA and high expression of *Arntl2* was associated with poor survival in LIHC and BRCA samples (Supplementary Figure 1). We found a positive correlation between *Klf10*, *Ntrk3*, *Igf1* and *Usp2* in almost all cancer samples. The DEG analyses are supported by immunohistochemistry analysis (Supplementary Figure 2-6, Figure 2-5).

IGF1 and ARNTL2 have been shown to play a role in immune modulation. Then, we investigate the association of their expression with immune cells in cancer. We found that their mRNA expressions were negatively associated with tumor purity and positively associated with infiltration of B Cells, CD8+ T cells, CD4+ T cells, Macrophages, Neutrophils and Dendritic cells (Supplementary Figure 7 and 8, respectively).

DISCUSSION

Over the last decade, substantial research has been undertaken to understand the multiple biological processes directed by endogenous clock genes that lead to type 2 DM and carcinogenesis. Integration of the genome-wide biological data with biomolecular networks is required to make a clear conclusion on mechanisms for signature of those diseases (Buttar et al., 2005; Prabhakar et al., 2014). In our previous study associating type 2 DM and cancer, we observed association of type 2 DM and renin-angiotensin biomarkers with breast, bladder, liver, pancreas, colon and rectum cancer and also a significant potential to be considered as systems-level biomarkers that may be used for screening or therapeutic purposes (Pereira et al., 2019). We are now analyzing those samples according to circadian rhythm-related genes.

The aim of our study is to identify the link between type 2 DM, circadian rhythm-related genes and cancer by analyzing animal-based research of sleep deprivation, type 2 DM samples and, BLCA, BRCA, COAD, LIHC, PAAD and READ cancer samples. We performed several analytical methods to determine the underlying molecular mechanisms. First, we detected downregulated and upregulated DEGs in mouse cortex and hypothalamus samples. The authors determine the changes by comparing expression in sleeping animals euthanized at different times during the lights on period, to that in animals sleep deprived and euthanized at the same diurnal time. In summary, upregulated genes active genes associated with oxidative phosphorylation, cancer and diabetes, mainly in hypothalamus specimens. In cortex, we observed mainly downregulation of immune system.

In mammals, light information is perceived by the retina and transmitted to the suprachiasmatic nuclei through the retinohypothalamic tract. The projections of the suprachiasmatic nuclei, have at least four neuronal targets: endocrine neurons, autonomic neurons of the paraventricular nucleus of the hypothalamus, other hypothalamic structures, and areas outside the hypothalamus (Bozek et al., 2009; de Oliveira et al., 2019). These efferent pathways are able to synchronize peripheral clocks, controlling various physiological functions, such as hormone releasing, food behavior and temperature fluctuations. It has been shown that shift work promotes sleep disturbances (Zhu and Zee, 2012). These disturbing external signals induce loss of coherence between the central oscillator and the peripherals and can lead to diseases that characterize the internal desynchronization: insomnia, cardiovascular disorders, obesity, depression, diabetes, dysregulation of metabolic rhythms and endocrine and even cancer. Several reports have revealed that clock genes are found to be deregulated in several cancer types. In comparison with surrounding non-cancerous cells, breast cancer cells reveal

disturbances in the expression of the clock genes attributable to methylation, which is associated with decreased gene expression (Basudhar et al., 2019; Soták et al., 2013; Zhu and Zee, 2012).

We first propose that sleeping disturbance in animal models could promote type 2 DM and cancer development, by hypothalamus and cortex gene expression deregulation. Next, DEGs were combined with 214 circadian rhythm related genes to type 2 DM and cancer samples. We observed that several common genes deregulated in both diseases. *Ntkr3*, *Igf1* and *Usp2* were both downregulated in type 2 DM and cancer samples, while *Arntl2* and *Agrp* were upregulated. It seems that the changes in mRNA are contributing to the phenotypic changes in type 2 DM, resulting in phenotypic changes associated with the malignant transformation. Taking those genes to perform a survival analysis, we found only *Igf1*, *Usp2* and *Arntl2* genes associated with patient outcomes. While *Igf1* and *Usp2* downregulation had a negative impact, *Arntl2* upregulation was associated with poor survival both in BLCA and BRCA cancer samples.

IGF1 is a mitogen for a variety of cells and exerts this action through the MAP kinase signaling pathway by increasing DNA synthesis and stimulating the expression of cyclin D1, which accelerates progression of the cell cycle from the G1 to S phase. The circulating IGF1 and IGF2 bind to IGF1 receptors (IGF1R) and trigger a signal transduction cascade (Shi et al., 2014). This signaling is very critical for the processes of oncogenesis. IGF1R activity is mediated by the Ras and AKT pathways and results in upregulation of cyclin D1 and its CDK4 linker, leading to retinoblastoma protein phosphorylation, release of the E2F transcription factor and expression of downstream target genes such as cyclin E. Plasma IGF1 level changes during the day, suggesting some circadian control, but molecular mechanisms are not clear. In our study, we observed downregulation of *Igf1* mRNA expression in several cancer types. However, protein analysis showed higher levels of IGF1 in cancer compared to normal samples. A previous study analyzing around-the-clock blood sampling, showed that both healthy and cancer individuals were found to be similarly synchronized to the 24-h sleep-wake schedule. However, growth hormone (GH)-IGF-1 axis function, cortisol secretion and IL-2 serum levels were altered in cancer patients. In cancer patients there was an increasing trend and progressive loss of circadian rhythmicity of GH secretion, accompanied by a decreasing of IGF-1 serum levels, upregulation of cortisol secretion and IL-2 serum levels. It has been well established that IGF1 promotes cancer cell proliferation, migration and metastasis. IGF1 has been shown to be controlled by CRY1/2 proteins. *Cry2* mRNA was downregulated in BLCA and BRCA samples in our study. However, we observed higher CRY2 protein expression in cancer samples. This data suggests that CRY2 could control IGF1 levels and these alterations may be related to the

process of carcinogenesis and, could favor cancer progression.

The deubiquitinating enzyme Ubiquitin Specific Protease 2 (USP2) is highly dependent on the circadian cycle, showing biological clock oscillations (Yang et al., 2012). It can be expressed under two isoforms, *Usp2a* and *Usp2b*. *Usp2b* has been shown having oscillations more dependent on circadian regulation. This enzyme has been reported as a stabilizer of *Bmall* gene (Scoma et al., 2011), and acts on the ubiquitination of *Per1*, a central gene, essential for the production of circadian behavioral rhythms. Animal models have shown that total inhibition of USP2 can compromise the rhythm circadian pathway thereby altering several other genes dependent on these biological oscillations. USP2 directly affects the levels of deubiquitinating proteins such as MDM2, cyclin D1 and CRY1 and their substrates, conferring resistance to apoptosis in mutated cells, acting as an oncogene. Since USP2 is the only enzyme capable of deubiquitinating cyclin D1 in human cells, cyclin D1 is reported as the most effective substrate for USP2.

Taking into account that several diseases can be triggered by circadian rhythm dysregulation, among them we can highlight diabetes and cancer (Renehan et al., 2012). The role of *Usp2* expression would be to induce prolonged fasting, occurring at the end of the clear phase of the circadian rhythm, thus stimulating the occurrence of hepatic gluconeogenesis. In addition, USP2 is required to maintain glucose homeostasis and regulate glucose tolerance through glucocorticoid signaling. Both circadian and USP2 deregulations accelerate the process of hepatic gluconeogenesis by increasing glucose secretion. Experiments have shown that a deregulated rhythm changes serum glucose levels, the development associated with glucocorticoid receptors. Excessive activity in glucocorticoid signaling may lead to the development of glucose intolerance. We suggest that changes in circadian rhythm and USP2 levels may be associated with the initiation and progression of type 2 diabetes, leading to cancer development. We also found that *Igf1* and *Usp2* expressions were negatively associated with tumor purity and positively associated with infiltration of B Cells, CD8+ T cells, CD4+ T cells, Macrophages, Neutrophils and Dendritic cells. Besides, TIMER analysis confirms that those genes overexpression are positively associated with macrophage population. The results show that these genes are playing an important role in immune modulation.

Taking all data together, we hypothesized that changes in the expression of circadian rhythm related-genes in type 2 DM and cancer could be responsible for metabolic changes that could lead to the cancer development. Such shifts in tissue metabolism results, at least in part, from profound recruitment of inflammatory cell types, particularly myeloid cells, such as neutrophils and monocytes. Expression of *Igf1* and *Usp2* may be associated with the immune

system in both the diabetes and cancer samples. These disturbances may lead to alterations in immunity by enhancing the infiltration of leukocytes and increased expression of pro-inflammatory cytokines. These diverse cells communicate with each other by means of direct contact or by cytokine and chemokine production and act in autocrine and paracrine manners to control and shape tumor growth and metastasis. Interestingly, we observed lower expression of ARNTL2 protein in cancer samples. This protein plays an important role in circadian rhythm system and it has been shown to be associated with immune escape mechanism. Besides, previous results have demonstrated that *Arntl2*, in association with *Nr1d1* and *Npas2* may function as an oncogene. This indicates that the altered expression levels of those genes could be associated with cancer progression and aggressive metastatic phenotype.

These biological molecules not only represent the association of type 2 DM and circadian rhythm biomarkers with breast, bladder, liver, pancreas, colon and rectum cancer but also have significant potential to be considered as systems-level biomarkers that may be used for screening or therapeutic purposes. Our data stimulate efforts in news studies to achieve the experimental and clinical validation about these biomolecules.

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

Not applicable.

REFERENCES

- Basudhar, D., Bharadwaj, G., Somasundaram, V., Cheng, R. Y. S., Ridnour, L. A., Fujita, M., Lockett, S. J., Anderson, S. K., McVicar, D. W. & Wink, D. A. (2019). Understanding the tumour micro-environment communication network from an NOS2/COX2 perspective. *Br. J. Pharmacol.* <https://doi.org/10.1111/bph.14488>
- Ben-Shlomo, R. (2014). Chronodisruption, cell cycle checkpoints and DNA repair. *Indian J. Exp. Biol.* <https://doi.org/24851401>
- Blair, A., Blask, D., Bråtveit, M., Brock, T., Burgess, J.L., Costa, G., Davis, S., Demers, P.A., Hansen, J., Haus, E., Landrigan, P.J., Lemasters, G.K., Lévi, F., Merletti, F., Portier, C.J., Pukkala, E., Schernhammer, E., Steenland, K., Stevens, R., Vermeulen, R., Zheng, T., Zhu, Y., Arendt, J., Austin, C., Cherrie, J., Huici-Montagud, A., Mundt, K., Altieri, A., Baan, R., Altieri, A., Baan, R., Bouvard, V., James Coglianò, V., Giannandrea, F., El Ghissassi, F., Grosse, Y., Heck, J., Mitchell, J., Napalkov, N., Secretan, B., Straif, K., Egraz, S., Javin, M., Kajo, B., Lézère, M., Lorenzen-Augros, H., Freeman, C., Guha, N., Galichet, L., Hameau, A.S., Moutinho, S. & Russell, D. (2010). Painting, firefighting, and shiftwork. *IARC Monogr. Eval. Carcinog. Risks to Humans* 98, 9–38.
- Borgs, L., Beukelaers, P., Vandenbosch, R., Belachew, S., Nguyen, L., Malgrange, B., 2009. Cell circadian cycle: New role for mammalian core clock genes. *Cell Cycle*. <https://doi.org/10.4161/cc.8.6.7869>
- Bozek, K., Relógio, A., Kielbasa, S.M., Heine, M., Dame, C., Kramer, A. & Herzog, H. (2009). Regulation of clock-controlled genes in mammals. *PLoS One*. <https://doi.org/10.1371/journal.pone.0004882>
- Buttar, H.S., Li, T. & Ravi, N. (2005). Prevention of cardiovascular diseases: Role of exercise, dietary interventions, obesity and smoking cessation. *Exp. Clin. Cardiol.*
- Cao, Y. & Wang, R. H. (2017). Associations among metabolism, circadian rhythm and age-associated diseases. *Aging Dis.* <https://doi.org/10.14336/AD.2016.1101>
- Chen, S. T., Choo, K. B., Hou, M. F., Yeh, K. T., Kuo, S. J. & Chang, J. G. (2005). Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. *Carcinogenesis* 26, 1241–1246. <https://doi.org/10.1093/carcin/bgi075>
- de Oliveira, I. G. B., Junior, M. D. F., Lopes, P. R., Campos, D. B. T., Ferreira-Neto, M. L., Santos, E. H. R., Mathias, P. C. de F., Francisco, F. A., Koike, B. D. V., de Castro, C. H., Freiria-Oliveira, A. H., Pedrino, G. R., Gomes, R. M. & Rosa, D. A. (2019). Forced internal desynchrony induces cardiometabolic alterations in adult rats. *J. Endocrinol.*

- 242, 25–36. <https://doi.org/10.1530/JOE-19-0026>
- Dunlap, J. C. (1999). Molecular Bases for Circadian Clocks. *Cell* 96, 271–290. [https://doi.org/10.1016/S0092-8674\(00\)80566-8](https://doi.org/10.1016/S0092-8674(00)80566-8)
- Fu, L., Pelicano, H., Liu, J., Huang, P. & Lee, C.C. (2002). The circadian gene *Period2* plays an important role in tumor suppression and DNA damage response in vivo. *Cell*. [https://doi.org/10.1016/S0092-8674\(02\)00961-3](https://doi.org/10.1016/S0092-8674(02)00961-3)
- Gery, S. & Koeffler, H. P. (2010). Circadian rhythms and cancer. *Cell Cycle*. <https://doi.org/10.4161/cc.9.6.11046>
- Gery, S., Komatsu, N., Baldjyan, L., Yu, A., Koo, D. & Koeffler, H. P. (2006). The Circadian Gene *Per1* Plays an Important Role in Cell Growth and DNA Damage Control in Human Cancer Cells. *Mol. Cell* 22, 375–382. <https://doi.org/10.1016/j.molcel.2006.03.038>
- Golombek, D. A., Casiraghi, L. P., Agostino, P. V., Paladino, N., Duhart, J. M., Plano, S. A. & Chiesa, J. J. (2013). The times they're a-changing: Effects of circadian desynchronization on physiology and disease. *J. Physiol. Paris* 107, 310–322. <https://doi.org/10.1016/j.jphysparis.2013.03.007>
- Gómez-Abellán, P., Hernández-Morante, J. J., Luján, J. A., Madrid, J. A. & Garaulet, M. (2008). Clock genes are implicated in the human metabolic syndrome. *Int. J. Obes.* 32, 121–128. <https://doi.org/10.1038/sj.ijo.0803689>
- Herichova, I., Zsoldosova, K., Vesela, A. & Zeman, M. (2014). Effect of angiotensin II infusion on rhythmic clock gene expression and local renin-angiotensin system in the aorta of Wistar rats. *Endocr. Regul.* 48, 144–151. https://doi.org/10.4149/endo_2014_03_144
- Hua, H., Wang, Y., Wan, C., Liu, Y., Zhu, B., Yang, C., Wang, X., Wang, Z., Cornelissen-Guillaume, G. & Halberg, F. (2006). Circadian gene *mPer2* overexpression induces cancer cell apoptosis. *Cancer Sci.* 97, 589–596. <https://doi.org/10.1111/j.1349-7006.2006.00225.x>
- International Agency for Research on Cancer (2019). IARC Monographs Meeting 124: Night Shift Work (4–11 June 2019) 124.
- Karatsoreos, I. N., Bhagat, S., Bloss, E. B., Morrison, J. H. & McEwen, B. S. (2011). Disruption of circadian clocks has ramifications for metabolism, brain, and behavior. *Proc. Natl. Acad. Sci.* 108, 1657–1662. <https://doi.org/10.1073/pnas.1018375108>
- Li, T., Fan, J., Wang, B., Traugh, N., Chen, Q., Liu, J. S., Li, B. & Liu, X. S. (2017). TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. *Cancer Res.* 77, e108–e110. <https://doi.org/10.1158/0008-5472.CAN-17-0307>

- Lowrey, P. L. & Takahashi, J. S. (2011). Genetics of circadian rhythms in mammalian model organisms. *Adv. Genet.* 74, 175–230. <https://doi.org/10.1016/B978-0-12-387690-4.00006-4>
- Ohashi, N., Isobe, S., Ishigaki, S. & Yasuda, H. (2017). Circadian rhythm of blood pressure and the renin–angiotensin system in the kidney. *Hypertens. Res.* 40, 413–422.
- Pereira, L. X., Alves da Silva, L. C., Feitosa, A. O., Ferreira, R. J. S., Duarte, A. K. F., Conceição, V., Marques, C. S., Rodrigues, A. K. B. F., Koike, B. D. V., Queiroz, A. C., Guimaraes, T. A., Souza, C. D. F. & Fraga, C. A. C. (2019). Correlation between renin–angiotensin system (RAS) related genes, type 2 diabetes, and cancer: Insights from metaanalysis of transcriptomics data. *Mol. Cell. Endocrinol.* 110455. <https://doi.org/10.1016/j.mce.2019.110455>
- Perelis, M., Marcheva, B., Ramsey, K. M., Schipma, M. J., Hutchison, A. L., Taguchi, A., Peek, C. B., Hong, H., Huang, W., Omura, C., Allred, A. L., Bradfield, C. A., Dinner, A. R., Barish, G. D. & Bass, J. (2015). Pancreatic b cell enhancers regulate rhythmic transcription of genes controlling insulin secretion. *Science* (80-.). <https://doi.org/10.1126/science.aac4250>
- Prabhakar, P. K., Kumar, A. & Doble, M. (2014). Combination therapy: A new strategy to manage diabetes and its complications. *Phytomedicine* 21, 123–130. <https://doi.org/10.1016/j.phymed.2013.08.020>
- Rana, S., Munawar, M., Shahid, A., Malik, M., Ullah, H., Fatima, W., Mohsin, S. & Mahmood, S. (2014). Deregulated expression of circadian clock and clock-controlled cell cycle genes in chronic lymphocytic leukemia. *Mol. Biol. Rep.* 41, 95–103. <https://doi.org/10.1007/s11033-013-2841-7>
- Reddy, A. B., Wong, G. K. Y., O’Neill, J., Maywood, E. S. & Hastings, M. H. (2005). Circadian clocks: Neural and peripheral pacemakers that impact upon the cell division cycle. *Mutat. Res. - Fundam. Mol. Mech. Mutagen.* 574, 76–91. <https://doi.org/10.1016/j.mrfmmm.2005.01.024>
- Renehan, A. G., Yeh, H. C., Johnson, J. A., Wild, S. H., Gale, E. A. M. & Møller, H. (2012). Diabetes and cancer (2): Evaluating the impact of diabetes on mortality In patients with cancer. *Diabetologia.* <https://doi.org/10.1007/s00125-012-2526-0>
- Saini, C., Petrenko, V., Pulimeno, P., Giovannoni, L., Berney, T., Hebrok, M., Howald, C., Dermitzakis, E. T. & Dibner, C. (2016). A functional circadian clock is required for proper insulin secretion by human pancreatic islet cells. *Diabetes, Obes. Metab.* <https://doi.org/10.1111/dom.12616>

- Scoma, H. D., Humby, M., Yadav, G., Zhang, Q., Fogerty, J. & Besharse, J. C. (2011). The de-ubiquitinating enzyme, USP2, is associated with the circadian clockwork and regulates its sensitivity to light. *PLoS One*. <https://doi.org/10.1371/journal.pone.0025382>
- Scott, E. M., Carter, A. M. & Grant, P. J. (2008). Association between polymorphisms in the Clock gene, obesity and the metabolic syndrome in man. *Int. J. Obes.* 32, 658–662. <https://doi.org/10.1038/sj.ijo.0803778>
- Shi, Y., Wang, J., Chandralapaty, S., Cross, J., Thompson, C., Rosen, N. & Jiang, X. (2014). PTEN is a protein tyrosine phosphatase for IRS1. *Nat. Struct. Mol. Biol.* <https://doi.org/10.1038/nsmb.2828>
- Soták, M., Polidarová, L., Ergang, P., Sumová, A. & Pácha, J. (2013). An association between clock genes and clock-controlled cell cycle genes in murine colorectal tumors. *Int. J. Cancer*. <https://doi.org/10.1002/ijc.27760>
- Yang, Y., Duguay, D., Bédard, N., Rachalski, A., Baquiran, G., Na, C. H., Fahrenkrug, J., Storch, K. F., Peng, J., Wing, S. S. & Cermakian, N. (2012). Regulation of behavioral circadian rhythms and clock protein PER1 by the deubiquitinating enzyme USP2. *Biol. Open*. <https://doi.org/10.1242/bio.20121990>
- Ye, D., Cai, S., Jiang, X., Ding, Y., Chen, K., Fan, C., Jin, M., 2016. Associations of polymorphisms in circadian genes with abdominal obesity in Chinese adult population. *Obes. Res. Clin. Pract.* 10, S133–S141. <https://doi.org/10.1016/j.orcp.2016.02.002>
- Yeh, K. T., Yang, M. Y., Liu, T. C., Chen, J. C., Chan, W. L., Lin, S. F. & Chang, J. G. (2005). Abnormal expression of Period 1 (PER1) in endometrial carcinoma. *J. Pathol.* 206, 111–120. <https://doi.org/10.1002/path.1756>
- Zhu, L. & Zee, P. C. (2012). Circadian Rhythm Sleep Disorders. *Neurol. Clin.* <https://doi.org/10.1016/j.ncl.2012.08.011>

Figure 1 -Venn Diagrams of differentially expressed genes in mRNA expression profiling datasets. We are showing downregulated (A) and upregulated (B) genes in human Beta Cells (GSE20966 and GSE25724), blood (GSE56931 and GSE26168), skeletal muscle (GSE29221), and liver (GSE23343). We are also showing downregulated and upregulated cancer samples (C and D, respectively) combined with clock gene list. The number in each intersecting region represents the number of overlapping genes. Volcano plots of differentially genes expression in breast invasive carcinoma (E), Colon Adenocarcinoma (F)Liver Hepatocellular carcinoma (G), Pancreas adenocarcinoma (H) and Rectum Adenocarcinoma (I). Red: up-regulation; green: down-regulation. *Klf10* (ENSG00000155090) was downregulated in BLCA, BRCA, LIHC and READ; *Ntrk3* (ENSG00000140538) and *Igf1* (ENSG00000017427) were downregulated in BLCA, BRCA, COAD, LIHC and READ; Similarly, *Klf9* (ENSG00000119138) and *Usp2* (ENSG00000036672) downregulation were found in BLCA, BRCA, COAD and READ. *Ezh2* (ENSG00000106462), *Cdk1* (ENSG00000170312), *Top2a* (ENSG00000131747), *Agrp* (ENSG00000159723), *Aanat* (ENSG00000129673) and *Ren* (ENSG00000143839) were upregulated in BLCA, BRCA, COAD and READ, while *Arntl2* (ENSG00000029153) was upregulated in BLCA, BRCA, COAD and READ.




Figure 2 - Representative immunohistochemical staining characteristics of ARNTL2 expressions in normal and cancer patients. Data are extracted from The Human Protein Atlas (<https://www.proteinatlas.org/>).




Figure 3 - Representative immunohistochemical staining characteristics of CRY2 expressions in normal and cancer patients. Data are extracted from The Human Protein Atlas (<https://www.proteinatlas.org/>).




Figure 4 - Representative immunohistochemical staining characteristics of IGF1 expressions in normal and cancer patients. Data are extracted from The Human Protein Atlas (<https://www.proteinatlas.org/>).







Figure 5 - Representative immunohistochemical staining characteristics of USP2 expressions in normal and cancer patients. Data are extracted from The Human Protein Atlas (<https://www.proteinatlas.org/>).




Supplementary Figure 1 - Kaplan-Meier analysis of *Klf10*, *Ppargc1a*, *Prkaa2*, *Per3*, *Igf1*, *Klf9*, *Usp2*, *Vip*, *Mapk10*, *Prokr1* and *nr3c1* in Bladder Urothelial Cancer (BLCA), breast invasive carcinoma (BRCA), Colon Adenocarcinoma (COAD), Liver Hepatocellular carcinoma (LIHC), Pancreas adenocarcinoma (PAAD) and Rectum Adenocarcinoma (READ). Data are extracted from TIMER web server. $P < 0,05$ was considered statistically significant.




Supplementary Figure 2 - Correlation between *Klf10*, *Ntrk3*, *Igf1* and *Usp2* in Bladder Urothelial Cancer (BLCA). Data are extracted from TIMER web server. $P < 0,05$ was considered statistically significant.




Supplementary Figure 3 - Correlation between *Klf10*, *Ntrk3*, *Igf1* and *Usp2* in Colon Adenocarcinoma (COAD). Data are extracted from TIMER web server. $P < 0,05$ was considered statistically significant.




Supplementary Figure 4 - Correlation between *Klf10*, *Ntrk3*, *Igf1* and *Usp2* in Pancreas adenocarcinoma (PAAD). Data are extracted from TIMER web server. $P < 0,05$ was considered statistically significant.




Supplementary Figure 5 - Correlation between *Klf10*, *Ntrk3*, *Igf1* and *Usp2* in Liver Hepatocellular carcinoma (LIHC). Data are extracted from TIMER web server. $P < 0,05$ was considered statistically significant.




Supplementary Figure 6 - Correlation between *Klf10*, *Ntrk3*, *Igf1* and *Usp2* in Rectum Adenocarcinoma (READ). Data are extracted from TIMER web server. $P < 0,05$ was considered statistically significant.



Supplementary Figure 7 - Correlation of IGF1 expression with immune infiltration level in in Bladder Urothelial Cancer (BLCA), breast invasive carcinoma (BRCA), Colon Adenocarcinoma (COAD), Liver Hepatocellular carcinoma (LIHC), Pancreas adenocarcinoma (PAAD) and Rectum Adenocarcinoma (READ). The scatterplots are generated and displayed after inputs are submitted successfully, showing the purity-corrected partial Spearman's correlation and statistical significance. Data are extracted from TIMER web server. $P < 0,05$ was considered statistically significant.



Supplementary Figure 8 - Correlation of ARNTL2 expression with immune infiltration level *in* in Bladder Urothelial Cancer (BLCA), breast invasive carcinoma (BRCA), Colon Adenocarcinoma (COAD), Liver Hepatocellular carcinoma (LIHC), Pancreas adenocarcinoma (PAAD) and Rectum Adenocarcinoma (READ). The scatterplots are generated and displayed after inputs are submitted successfully, showing the purity-corrected partial Spearman's correlation and statistical significance. Data are extracted from TIMER web server. $P < 0,05$ was considered statistically significant.



Supplementary Table 1 - Functional annotation analysis of downregulated differentially expressed genes in hypothalamus (GSE6514) intersected datasets using the DAVID tool. Mice were euthanized following 3 hrs of total sleep deprivation. $P < 0,05$ was considered statistically significant.

Term	PValue	Genes
mmu00830:Retinol metabolism	0.02694143573768382	RDH12, ALDH1A2, CYP26B1, RDH16
mmu04610: Complement and coagulation cascades	0.034646624863555325	F13B, C5AR1, FGA, BDKRB2
mmu04310:Wnt signaling pathway	0.05366751510526847	CSNK1A1, NKD2, PRICKLE1, PPP2CB, FZD3

Supplementary Table 2 - Functional annotation analysis of upregulated differentially expressed genes in hypothalamus (GSE6514) intersected datasets using the DAVID tool. Mice were euthanized following 3 hrs of total sleep deprivation. $P < 0,05$ was considered statistically significant.

Term	PValue	Genes
mmu04070:Phosphatidylinositol signaling system	0.011670372 824607887	PRKCA, DGKG, PLCD3, PLCD4, ITPR3
mmu04512:ECM-receptor interaction	0.074857973 33737988	ITGA9, TNC, ITGB1, COL4A6
mmu04020:Calcium signaling pathway	0.075004981 14905663	PRKCA, EDNRA, ATP2A2, PLCD3, PLCD4, ITPR3
mmu05222: Small cell lung cancer	0.079162015 86803795	TRAF1, ITGB1, TRAF4, COL4A6
mmu04510:Focal adhesion	0.084543745 6343312	PRKCA, ITGA9, TNC, FLNC, ITGB1, COL4A6
mmu05200:Pathways in câncer	0.086267420 06122387	TRAF1, PRKCA, FGF14, NKX3-1, ITGB1, TRAF4, STAT3, COL4A6

Supplementary Table 3 - Functional annotation analysis of downregulated differentially expressed genes in hypothalamus (GSE6514) intersected datasets using the DAVID tool. Mice were euthanized following 6 hrs of total sleep deprivation. $P < 0,05$ was considered statistically significant.

Term	PValue	Genes
mmu04722:Neurotrophin signaling pathway	1,70E-06	IRS4, TRP53, PIK3CD, MAPK10, KIDINS220, IRAK4, NTRK3, IRAK3, CRKL, RPS6KA4, CAMK4, RPS6KA2, SOS1, MAPK14, NTRK2, CAMK2D, MAPK8, IKBKB, CAMK2A, MAP2K7, PIK3R1, AKT3
mmu05200:Pathways in cancer	1,14E-05	BID, FGFR1, XIAP, APC2, STK36, STAT5B, BCL2L1, KIT, CTNNB1, TPM3, WNT1, SOS1, ITGAV, TPR, PIK3R1, AKT3, APC, DVL2, TRP53, BCR, PIK3CD, FZD1, SKP2, ITGA3, MAPK10, CTNNA3, FZD6, WNT7B, FZD10, CRKL, PIAS3, PDGFRA, PDGFRB, MDM2, MAPK8, IKBKB
mmu04310:Wnt signaling pathway	1,56E-05	TRP53, DVL2, TBL1XR1, APC2, BTRC, FZD1, MAPK10, FZD6, CTNNB1, CSNK2A2, MAP3K7, WNT1, FZD10, WNT7B, PLCB4, CCND2, NFAT5, CAMK2D, MAPK8, PRKACB, CAMK2A, APC
mmu04910:Insulin signaling pathway	1,64E-05	IRS4, PHKA1, PIK3CD, PRKAB2, MKNK2, HK1, MAPK10, PRKAR2B, PRKAR2A, PPP1R3C, CRKL, INPP5K, SLC2A4, GCK, SOS1, PRKAR1B, MAPK8, PRKACB, IKBKB, AKT3, PIK3R1
mmu05210:Colorectal cancer	2,10E-05	TRP53, DVL2, APC2, PIK3CD, FZD1, MAPK10, FZD6, CTNNB1, FZD10, SOS1, PDGFRA, PDGFRB, MAPK8, AKT3, PIK3R1, APC
mmu04930:Type II diabetes mellitus	2,37E-05	IRS4, GCK, SLC2A4, PIK3CD, HK1, MAPK8, MAPK10, PRKCE, IKBKB, KCNJ11, PIK3R1, CACNA1B
mmu04210:Apoptosis	2,42E-05	BID, TRP53, XIAP, PIK3CD, BCL2L1, IRAK4, PRKAR2B, IRAK3, PRKAR2A, PRKAR1B, APAF1, PRKACB, IKBKB, AKT3, IL3RA, PIK3R1
mmu04010:MAPK signaling pathway	1,41E-04	FGFR1, MKNK2, PPM1B, MAP3K7, SOS1, PRKACB, MAP2K7, AKT3, TRP53, CACNA2D1, CACNG3, MAPK10, FLNB, STK3, DDIT3, RPS6KA4, CRKL, RASGRF2, RPS6KA2, MAPK14, NTRK2, PDGFRA, MAPK8IP3, PDGFRB, MAPK8, IKBKB, DUSP8, PPP5C, CACNA1B
mmu05217:Basal cell carcinoma	3,59E-04	DVL2, TRP53, WNT1, FZD10, WNT7B, APC2, STK36, FZD1, FZD6, CTNNB1, APC
mmu04916:Melanogenesis	4,48E-04	DVL2, ADCY3, ADCY7, FZD1, KIT, FZD6, CTNNB1, WNT1, FZD10, WNT7B, PLCB4, CAMK2D, GNAS, PRKACB, CAMK2A
mmu04062:Chemokine	0,001953580933429	ADCY3, PARD3, ADCY7, PIK3CD, STAT5B, CX3CL1, ELMO1, CCR9, CCL25, CRKL, PLCB4,

signaling pathway		TIAM1, SOS1, CX3CR1, CCR2, GNG2, PRKACB, IKBKB, AKT3, PIK3R1
mmu04912:GnRH signaling pathway	0,003324 67696788 8	ADCY3, PLD1, ADCY7, MAPK10, PLCB4, MAPK14, SOS1, CAMK2D, MAPK8, GNAS, PRKACB, CAMK2A, MAP2K7
mmu04120:Ubiquitin mediated proteolysis	0,003386 64678245 7	XIAP, UBE4A, BTRC, SKP2, KEAP1, UBE2I, UBE2H, UBE2B, CDC27, MGRN1, PIAS3, UBE2K, NEDD4, MDM2, SMURF1, TRIP12
mmu05222:Small cell lung cancer	0,003421 47353034 9	TRP53, XIAP, PIAS3, ITGAV, PIK3CD, SKP2, ITGA3, BCL2L1, APAF1, IKBKB, PIK3R1, AKT3
mmu04070:Phosphatidylinositol signaling system	0,004162 53760426 6	PLCB4, DGKB, INPP5K, PIK3C2A, DGKG, PIK3CD, PIKFYVE, PIP5K1C, SYNJ2, PIK3R1, PIP4K2C
mmu05213:Endometrial cancer	0,004166 74275270 8	TRP53, APC2, SOS1, PIK3CD, PIK3R1, CTNNA3, AKT3, CTNNB1, APC
mmu05214:Glioma	0,004506 66168915 7	TRP53, SOS1, PIK3CD, CAMK2D, PDGFRA, PDGFRB, MDM2, CAMK2A, PIK3R1, AKT3
mmu05220:Chronic myeloid leukemia	0,004584 85955340 4	TRP53, BCR, CRKL, SOS1, STAT5B, PIK3CD, MDM2, BCL2L1, IKBKB, PIK3R1, AKT3
mmu04520:Adherens junction	0,004584 85955340 4	PTPRB, CSNK2A2, MAP3K7, FGFR1, PARD3, WASF3, SSX2IP, YES1, CTNNA3, CTNNB1, FARP2
mmu04510:Focal adhesion	0,005041 25667864	XIAP, TLN2, PIK3CD, PIP5K1C, ITGA3, MAPK10, FLNB, CTNNB1, CRKL, CCND2, ITGA5, SOS1, ITGAV, PDGFRA, PDGFRB, MAPK8, AKT3, PARVB, PIK3R1, PARVA
mmu04914:Progesterone-mediated oocyte maturation	0,010085 21196957 7	ADCY3, ADCY7, RPS6KA2, MAPK14, PIK3CD, MAPK8, MAPK10, PRKACB, CDC27, PIK3R1, AKT3
mmu04620:Toll-like receptor signaling pathway	0,010820 21430612 6	IRAK4, MAP3K7, IFNAR2, TOLLIP, MAPK14, PIK3CD, MAPK8, MAPK10, IKBKB, MAP2K7, PIK3R1, AKT3
mmu04540:Gap junction	0,010918 59030232 7	ADCY3, PLCB4, ADCY7, CSNK1D, SOS1, PDGFRA, PDGFRB, GNAS, GUCY1B3, PRKACB, HTR2C
mmu04012:ErbB signaling pathway	0,011803 26535751 9	CRKL, SOS1, STAT5B, PIK3CD, CAMK2D, MAPK8, MAPK10, MAP2K7, CAMK2A, PIK3R1, AKT3
mmu04810:Regulation of	0,013078 79643093 9	GNA13, FGFR1, APC2, SSH1, PIK3CD, NCKAP1L, PIP5K1C, ITGA3, ITGAM, CRKL, ITGA5, TIAM1,

actin cytoskeleton		SOS1, ITGAV, PIKFYVE, PDGFRA, PDGFRB, PIP4K2C, PIK3R1, APC
mmu05215:Prostate cancer	0,014783 94290592 3	TRP53, FGFR1, SOS1, PIK3CD, PDGFRA, PDGFRB, MDM2, IKBKB, PIK3R1, AKT3, CTNNB1
mmu04020:Calcium signaling pathway	0,015843 97571717 5	SLC8A3, ADCY3, TRPC1, ADCY7, PHKA1, PLCB4, CAMK4, ATP2A2, ATP2A3, PDE1C, CAMK2D, PDGFRA, PDGFRB, GNAS, PRKACB, HTR2C, CAMK2A, CACNA1B
mmu05414:Dilated cardiomyopathy	0,017062 03690947 4	ADCY3, CACNA2D1, ATP2A2, ADCY7, ITGA5, ITGAV, GNAS, ITGA3, CACNG3, PRKACB, TPM3
mmu00562:Inositol phosphate metabolism	0,018032 55562798	PLCB4, INPP5K, PIK3C2A, PIK3CD, PIKFYVE, PIP5K1C, SYNJ2, PIP4K2C
mmu02010:ABC transporters	0,024479 43860889 4	ABCB8, ABCB1B, ABCC10, ABCC12, ABCA1, ABCB7, ABCC6
mmu04144:Endocytosis	0,025955 94320513 8	PLD1, PARD3, DNMI1L, LDLR, STAM2, PIP5K1C, KIT, RAB11FIP4, RAB11FIP3, TFRC, ACAP3, NEDD4, PIKFYVE, PDGFRA, DNAJC6, MDM2, SMURF1, RAB11FIP1
mmu05212:Pancreatic cancer	0,027838 02150986 8	TRP53, PLD1, PIK3CD, MAPK8, BCL2L1, MAPK10, IKBKB, PIK3R1, AKT3
mmu04660: T cell receptor signaling pathway	0,035403 43213552 3	MAP3K7, BCL10, CD40LG, SOS1, MAPK14, PIK3CD, NFAT5, IKBKB, MAP2K7, PIK3R1, AKT3, DLG1
mmu04130: SNARE interactions in vesicular transport	0,040755 05517889 1	STX17, GOSR2, VAMP3, VAMP2, GOSR1, STX1B
mmu04630: Jak-STAT signaling pathway	0,042967 08372493 9	STAM2, PIK3CD, STAT5B, BCL2L1, IL7R, IFNAR2, PRLR, PIAS3, CCND2, SOS1, IL13RA1, PIK3R1, AKT3, IL3RA
mmu04664: Fc epsilon RI signaling pathway	0,054010 54951779	SOS1, MAPK14, PIK3CD, MAPK8, MAPK10, PRKCE, MAP2K7, PIK3R1, AKT3
mmu04666: Fc gamma R-mediated phagocytosis	0,058455 97437169 3	PLD1, CRKL, DNMI1L, WASF3, PIK3CD, PIKFYVE, PIP5K1C, PRKCE, PIK3R1, AKT3
mmu05218:Melanoma	0,065976 65686755 9	TRP53, FGFR1, PIK3CD, PDGFRA, PDGFRB, MDM2, PIK3R1, AKT3

mmu05221:Acute myeloid leukemia	0,066302 38935643 4	SOS1, STAT5B, PIK3CD, KIT, IKBKB, PIK3R1, AKT3
mmu05412: Arrhythmogenic right ventricular cardiomyopathy (ARVC)	0,083302 61152267 4	CACNA2D1, ATP2A2, ITGA5, ITGAV, ITGA3, CACNG3, CTNNA3, CTNNB1

Supplementary Table 4 - Functional annotation analysis of upregulated differentially expressed genes in hypothalamus (GSE6514) intersected datasets using the DAVID tool. Mice were euthanized following 6 hrs of total sleep deprivation. $P < 0,05$ was considered statistically significant.

Term	PValue	Genes
mmu00190:Oxidative phosphorylation	4,69E-07	NDUFA4, NDUFA5, ATP5E, ATP5J2, NDUFA3, COX7A2, COX8B, ATP4B, COX6C, UQCR11, UQCRH, COX6A2, ATP5L, ATP5O, ATP5K, UQCRB
mmu05012:Parkinson's disease	8,51E-05	NDUFA4, NDUFA5, ATP5E, COX7A2, NDUFA3, COX8B, COX6C, UQCR11, CASP9, UQCRH, COX6A2, ATP5O, UQCRB
mmu05016:Huntington's disease	1,32E-04	NDUFA4, NDUFA5, ATP5E, NDUFA3, POLR2E, COX7A2, COX8B, COX6C, UQCR11, CASP9, UQCRH, COX6A2, TGM2, ATP5O, UQCRB
mmu05010:Alzheimer's disease	4,53E-04	NDUFA4, NDUFA5, ATP5E, COX7A2, NDUFA3, COX8B, COX6C, UQCR11, CASP9, UQCRH, BACE2, COX6A2, ATP5O, UQCRB
mmu04260:Cardiac muscle contraction	0,002760 52945879 4	FXVD2, UQCR11, COX7A2, COX8B, UQCRH, COX6A2, COX6C, UQCRB
mmu03010:Ribosome	0,065553 36507805 8	RPL41, RPL35, RPL27, RPS27L, RPL37, RPS24
mmu00410:beta-Alanine metabolism	0,099424 52102923 5	ALDH2, DPYS, AOC3

Supplementary Table 5 - Functional annotation analysis of downregulated differentially expressed genes in hypothalamus (GSE6514) intersected datasets using the DAVID tool. Mice were euthanized following 9 hrs of total sleep deprivation. $P < 0,05$ was considered statistically significant.

Term	PValue	Genes
mmu04020:Calcium signaling pathway	0,045568518 049453	EGFR, PLCZ1, P2RX1, CACNA1H, PLCD1, IGH-VJ558
mmu04010:MAPK signaling pathway	0,053398346 139521	EGFR, MAP3K7, RPS6KA3, RELB, CACNA1H, MAP3K14, FGF3

Supplementary Table 6 - Functional annotation analysis of upregulated differentially expressed genes in hypothalamus (GSE6514) intersected datasets using the DAVID tool. Mice were euthanized following 9 hrs of total sleep deprivation. $P < 0,05$ was considered statistically significant.

Term	PValue	Genes
mmu05200:Pathways in cancer	0,013810995 520305	TCF7, CYCT, SKP2, FZD1, FZD3, ZBTB16, CBLC, LAMA3, ITGAV, PAX8, PTCH1, IKBKB, FGF2, MMP1B
mmu04950: Maturity onset diabetes of the young	0,015265675 716387	HNF1B, IAPP, HNF4G, PDX1
mmu04672: Intestinal immune network for IgA production	0,023738635 669089	CCR9, IGHG, CD80, H2-DMB2, IL2
mmu04650: Natural killer cell mediated cytotoxicity	0,037758267 809113	KLRA16, CD48, IGHG, CD244, TNFRSF10B, KLRA7, VAV2
mmu05016:Huntington's disease	0,079202055 043023	SLC25A31, NDUFS4, CYCT, CREB1, CYP4A31, NDUFC2, PLCB2, POLR2A
mmu04330:Notch signaling pathway	0,081200303 679975	NOTCH2, NOTCH4, NUMB, LFNG
mmu04514: Cell adhesion molecules (CAMs)	0,093775924 821431	SELP, SIGLEC1, CD80, ITGAV, NLGN1, CD2, H2-DMB2
mmu04020:Calcium signaling pathway	0,094298620 512485	IGHG, SLC25A31, ERBB4, PDE1C, PLCD4, PLCB2, PTAFR, CACNA1A
mmu05222: Small cell lung cancer	0,094733504 181432	LAMA3, CYCT, ITGAV, SKP2, IKBKB

Supplementary Table 7 - Functional annotation analysis of downregulated differentially expressed genes in hypothalamus (GSE6514) intersected datasets using the DAVID tool. Mice were euthanized following 12 hrs of total sleep deprivation. $P < 0,05$ was considered statistically significant.

Term	PValue	Genes
mmu05210:Colorectal cancer	0,0245145411 11056	DVL2, DVL3, MSH2, PDGFRB
mmu04916:Melanogenesis	0,0361108994 48509	DVL2, WNT1, DVL3, POMC
mmu05217:Basal cell carcinoma	0,0608645321 83204	DVL2, WNT1, DVL3
mmu04310:Wnt signaling pathway	0,0945999234 20952	DKK2, DVL2, WNT1, DVL3

Supplementary Table 8 - Functional annotation analysis of upregulated differentially expressed genes in hypothalamus (GSE6514) intersected datasets using the DAVID tool. Mice were euthanized following 12 hrs of total sleep deprivation. $P < 0,05$ was considered statistically significant.

Term	PValue	Genes
mmu03320: PPAR signaling pathway	0,0324879268 31281	LPL, FABP2, CYP4A14, MMP1B, PCK1
mmu04060: Cytokine-cytokine receptor interaction	0,0327089562 67818	CSF2, INHBA, TNFRSF9, IL22RA1, IL5, PRLR, MET, TNFRSF14, HGF
mmu04950: Maturity onset diabetes of the young	0,0595843084 47436	HNF4A, HNF4G, NR5A2

Supplementary Table 9 - Functional annotation analysis of downregulated differentially expressed genes in cortex (GSE6514) intersected datasets using the DAVID tool. Mice were euthanized following 3 hrs of total sleep deprivation. $P < 0,05$ was considered statistically significant.

Term	PValue	Genes
mmu04514: Cell adhesion molecules (CAMs)	0,0332646588 79409	H2-K1, CLDN3, H2-D1, CD4, VCAN, ITGB1, SELE
mmu00480:Glutathione metabolismo	0,0475189510 45075	GSTA2, GSTA3, GPX3, MGST1
mmu00562:Inositol phosphate metabolismo	0,0521672395 72602	PIK3CG, MIOX, PLCD1, PI4KB
mmu04020:Calcium signaling pathway	0,0784822409 08623	GNA14, P2RX1, ADORA2A, ADRA1B, AVPR1A, PLCD1, GNAS

Supplementary Table 10 - Functional annotation analysis of upregulated differentially expressed genes in cortex (GSE6514) intersected datasets using the DAVID tool. Mice were euthanized following 3 hrs of total sleep deprivation. $P < 0,05$ was considered statistically significant.

Term	PValue	Genes
mmu04010:MAPK signaling pathway	0,0692979688 18719	MAP4K3, DUSP4, RASGRF2, FGF17, HSPB1, HSPA1B, FLNC

Supplementary Table 11 - Functional annotation analysis of downregulated differentially expressed genes in cortex (GSE6514) intersected datasets using the DAVID tool. Mice were euthanized following 6 hrs of total sleep deprivation. $P < 0,05$ was considered statistically significant.

Term	PValue	Genes
mmu04514: Cell adhesion molecules (CAMs)	0,0086273913 23092	SDC1, H2-Q10, CD80, H2-D1, CD2, VCAN, MADCAM1, ITGA4, ITGB1
mmu00983:Drug metabolismo	0,0126226927 3448	CYP3A25, UGT2B5, UPP2, DPYD, UGT2A3
mmu05416:Viral myocarditis	0,0326061736 70026	BID, H2-Q10, CD80, CYCT, H2-D1, MYH4
mmu00980: Metabolism of xenobiotics by cytochrome P450	0,0361197691 05627	CYP3A25, UGT2B5, UGT2A3, CYP2C50, MGST2
mmu00140:Steroid hormone biosynthesis	0,0532089649 93145	CYP3A25, UGT2B5, UGT2A3, CYP19A1
mmu00982:Drug metabolismo	0,0536001794 65743	CYP3A25, UGT2B5, UGT2A3, CYP2C50, MGST2
mmu04610: Complement and coagulation cascades	0,0536001794 65743	F11, FGG, FGA, SERPINA1B, C3
mmu00563: Glycosylphosphatidylinositol (GPI)-anchor biosynthesis	0,0808295544 93124	PIGB, PIGU, PIGN
mmu04672: Intestinal immune network for IgA production	0,0824484967 50621	CCR9, CD80, MADCAM1, ITGA4
mmu05332: Graft-versus-host disease	0,0972505016 23575	H2-Q10, CD80, H2-D1, KLRA7

Supplementary Table 12 - Functional annotation analysis of upregulated differentially expressed genes in cortex (GSE6514) intersected datasets using the DAVID tool. Mice were euthanized following 6 hrs of total sleep deprivation. $P < 0,05$ was considered statistically significant.

Term	PValue	Genes
mmu00052:Galactose metabolism	0,0349193235 07812	G6PC, GLA, HK3

Supplementary Table 13 - Functional annotation analysis of downregulated differentially expressed genes in cortex (GSE6514) intersected datasets using the DAVID tool. Mice were euthanized following 9 hrs of total sleep deprivation. $P < 0,05$ was considered statistically significant.

Term	PValue	Genes
mmu05330:Allograft rejection	0,0151323158 98876	IGHG, CD80, H2-OB, IGH-VJ558, H2-T3
mmu04650:Natural killer cell mediated cytotoxicity	0,0152433207 62071	IGHG, H60A, PTPN6, CSF2, CD247, NFAT5, IGH-VJ558
mmu05310:Asthma	0,0167515606 25554	IGHG, IL3, H2-OB, IGH-VJ558
mmu04080:Neuroactive ligand-receptor interaction	0,0274243255 73514	P2RX5, ADRB3, P2RY10, P2RY6, ADORA2B, AGTR1B, RXFP1, FPR3, NMBR, GH
mmu05320:Autoimmune thyroid disease	0,0308333461 82776	IGHG, CD80, H2-OB, IGH-VJ558, H2-T3
mmu04640:Hematopoietic cell lineage	0,0498677160 5983	IGHG, CSF2, IL3, DNMT, IGH-VJ558
mmu04672:Intestinal immune network for IgA production	0,0595032913 24067	IGHG, CD80, H2-OB, IGH-VJ558
mmu05416:Viral myocarditis	0,0697171118 10456	IGHG, CD80, H2-OB, IGH-VJ558, H2-T3
mmu04020:Calcium signaling pathway	0,0959357401 11107	P2RX5, IGHG, ADRB3, ADORA2B, AGTR1B, CACNA1A, IGH-VJ558

Supplementary Table 14 - Functional annotation analysis of upregulated differentially expressed genes in cortex (GSE6514) intersected datasets using the DAVID tool. Mice were euthanized following 9 hrs of total sleep deprivation. $P < 0,05$ was considered statistically significant.

Term	PValue	Genes
mmu04060:Cytokine-cytokine receptor interaction	0,0948137645 13206	CCR9, INHBA, TNFRSF25, CXCL15, TNFRSF14

Supplementary Table 15 - Functional annotation analysis of downregulated differentially expressed genes in cortex (GSE6514) intersected datasets using the DAVID tool. Mice were euthanized following 12 hrs of total sleep deprivation. $P < 0,05$ was considered statistically significant.

Term	PValue	Genes
mmu04080:Neuroactive ligand-receptor interaction	0,016453625084603	GALR1, PRLR, TACR3, PRSS2, DRD4, VIPR1, PTAFR, GH

Supplementary Table 16- Functional annotation analysis of upregulated differentially expressed genes in cortex (GSE6514) intersected datasets using the DAVID tool. Mice were euthanized following 12 hrs of total sleep deprivation. $P < 0,05$ was considered statistically significant.

Term	PValue	Genes
mmu05416:Viral myocarditis	0,0096939424 63592	CYCT, MYH2, H2-D1, H2-AA, H2-DMA, IGH-VJ558
mmu05310:Asthma	0,0105400029 41723	H2-AA, MS4A2, H2-DMA, IGH- VJ558
mmu05330:Allograft rejection	0,0465710277 14215	H2-D1, H2-AA, H2-DMA, IGH- VJ558
mmu05320:Autoimmune thyroid disease	0,0785341939 61941	H2-D1, H2-AA, H2-DMA, IGH- VJ558

5.2 PRODUTO 2

Patente: Privilégio de Inovação. Número do registro: BR10202002668, título: "Painel genético para diagnóstico e prognóstico do câncer de mama", Instituição de registro: INPI - Instituto Nacional da Propriedade Industrial. Depósito: 24/12/2020

5 CONCLUSÕES

Compilando todos os dados, a hipótese aventada foi de que mudanças na expressão de genes relacionados ao ritmo circadiano no diabetes mellitus tipo 2 e no câncer podem ser responsáveis por mudanças metabólicas que podem levar ao desenvolvimento do câncer. Essas mudanças no metabolismo do tecido resultam, pelo menos em parte, do recrutamento profundo de tipos de células inflamatórias, particularmente células mielóides, como neutrófilos e monócitos. A expressão de IGF-1 e USP2 pode estar associada ao sistema imunológico nas amostras de diabetes e câncer, esses distúrbios podem levar a alterações na imunidade ao aumentar a infiltração de leucócitos e aumentar a expressão de citocinas pró-inflamatórias. Essas diversas células comunicam-se entre si por meio de contato direto ou pela produção de citocinas e quimiocinas e agem de maneira autócrina e parácrina para controlar e moldar o crescimento tumoral e metástase. Curiosamente, observamos menor expressão da proteína ARNTL2 em amostras de câncer. Esta proteína desempenha um papel importante no sistema de ritmo circadiano e está associada ao mecanismo de escape imunológico, níveis de expressão alterados desses genes podem estar associados à progressão do câncer e ao fenótipo metastático agressivo.

Essas moléculas biológicas não apenas representam a associação de diabetes mellitus tipo 2 e biomarcadores de ritmo circadiano com câncer de mama, bexiga, fígado, pâncreas, cólon e reto, mas também têm potencial significativo para serem consideradas como biomarcadores em nível de sistema que podem ser usados para triagem ou finalidades terapêuticas, podendo levar a uma medicina de precisão, onde o tratamento é individualizado, garantindo melhores resultados para o paciente, assim como priorizará a fármaco-economia, selecionando quais pacientes serão realmente beneficiados com as drogas, economizando recursos públicos e particulares e evitando que pessoas recebam medicamentos que pouco as beneficiariam e ainda iriam infligir toxicidade decorrente dos mesmos. Nossos dados estimulam esforços em novos estudos para alcançar a validação experimental e clínica sobre essas biomoléculas.

REFERÊNCIAS

AMERICAN DIABETES ASSOCIATION. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes - 2019. **Diabetes Care**, v. 42, n. 1, p.S13-S28, jan. 2019.

AMERICAN DIABETES ASSOCIATION. Standards of medical care in diabetes. **Diabetes Care**, v. 42, n. 1, p:S1-193, jan. 2019.

AMERICAN DIABETES ASSOCIATION. Standards of Medical Care in Diabetes. **Ann Intern Med**, v. 166, n. 8, p.572-8, jan. 2017.

AKASH, M. S. H.; REHMAN, K.; LIAQAT, A. Tumor Necrosis Factor-Alpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus. **Journal of Cellular Biochemistry**, v. 119, n. 1, p. 105–110, 2018.

ALBERTI, K. G. M. M *et al.* Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International. **Circulation**, v. 120, n. 16, p. 1640–1645, 2009.

BHATT, H. B.; SMITH, R.J. Fatty liver disease in diabetes *mellitus*. **HepatoBiliary Surgery and Nutrition**, v.4, n.2, p.101-108, 2015.

BASUDHAR, D. *et al.* Understanding the tumour micro-environment communication network from an NOS2/COX2 perspective. **British Journal of Pharmacology**, v. 176, n. 2, p. 155–176, 2019.

BATTELLI, M. G.; BORTOLOTTI, M.; POLITO, L.; BOLOGNESI, A. Metabolic syndrome and cancer risk: The role of xanthine oxidoreductase. **Redox Biology**, v. 21, p. 101070, 2019.

BELLASTELLA, G. *et al.* Metabolic syndrome and cancer: “The common soil hypothesis”. **Diabetes Research and Clinical Practice**, v. 143, p. 389 – 397, 2018.

BERGER, J. A two-clock model of circadian timing in the immune system of mammals. **Pathologie Biologie**, v. 56, n. 5, p. 286 – 291, 2008.

BITZUR, R. *et al.* Metabolic syndrome, obesity, and the risk of cancer development. **European Journal of Internal Medicine**, v. 34, p. 89 – 93, 2016.

BOZEK, K. *et al.* Regulation of Clock-Controlled Genes in Mammals. **PloS one**, v. 4, n. 3, p. 482, 2009.

BRAUNA, S.; BITTON-WORMS, K.; LE ROITH, D. The link between the metabolic syndrome and cancer. **International Journal of Biological Sciences**, v. 7, n. 7, p. 1003 – 1015, 2011.

BUONO, G.; CRISPO, A.; GIULIANO, M.; *et al.* Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study. **Oncotarget**, v. 8, n. 70, p. 115709 – 115717, 2017.

BURDELAK, W.; BUKOWSKA, A.; KRYSICKA, J.; PEPLŃSKA, B. Night work and health status of nurses and midwives. Cross-sectional study. **Medycyna Pracy**, v. 63, n. 5, p. 517 – 529, 2012.

BUTTAR, H. S.; LI, T.; RAVI, N. Prevention of cardiovascular diseases: Role of exercise, dietary interventions, obesity and smoking cessation. **Experimental and Clinical Cardiology**, v. 10, n. 4, p. 229 – 249, 2005.

CALIMLIOGLU, B. *et al.* Tissue-specific molecular biomarker signatures of type 2 diabetes: an integrative analysis of transcriptomics and protein-protein interaction data. **Omic: A Journal of integrative Biology**, v.19, n.9, p.563 - 573, 2015.

COHEN, D. H.; LEROITH, D. Obesity, type 2 diabetes, and cancer: The insulin and IGF connection. **Endocrine-Related Cancer**, v. 19, n. 5, p. 27 – 45, 2012.

DANTAS, E. L. R.; SÁ, F. H. L. Genética do câncer hereditário. **Revista Brasileira de Cancerologia**, v. 55, n. 3, p. 263 - 269, 2009

DE BACQUER, D. *et al.* Rotating shift work and the metabolic syndrome: A prospective study. **International Journal of Epidemiology**, v. 38, n. 3, p. 848 – 854, 2009.

DE CAMPOS, F. G. C. M. *et al.* Incidência de câncer colorretal em pacientes jovens. **Revista do Colégio Brasileiro de Cirurgiões**, v. 44, n. 2, p. 208 – 215, 2017.

DEEPTHI, B. *et al.* A Modern Review of Diabetes Mellitus: An Annihilatory Metabolic Disorder. **Journal In Silico In Vitro Pharmacology**, v. 3, n. 1, p. 14 - 18, fev. 2017.

DE OLIVEIRA, I. G. B. *et al.* Forced internal desynchrony induces cardiometabolic alterations in adult rats. **Journal of Endocrinology**, v. 242, n. 2, p. 25 – 36, 2019.

DEL PUERTO-NEVADO, L. *et al.* 2017 Update on the Relationship Between Diabetes and Colorectal Cancer: Epidemiology, Potential Molecular Mechanisms and Therapeutic Implications. **Oncotarget**, v. 8, n. 11, p. 18456–18485, 2017.

DHARMALINGAM, M.; MARCUS, S. R. Pathogenetic Mechanism of Type 2 Diabetes Mellitus and its Clinical Implications. **Annals of the National Academy of Medical Sciences**, India, v. 55, n. 3, p. 132 – 134, 2019.

ESPOSITO, K. *et al.* Metabolic syndrome and risk of cancer: A systematic review and meta-analysis. **Diabetes Care**, v. 35, n. 11, p. 2402 – 2411, 2012.

GALLAGHER, E. J.; LEROITH, D. Obesity and diabetes: The increased risk of cancer and cancer-related mortality. **Physiological Reviews**, v. 95, n. 3, p. 727 – 748, 2015.

GERY, S.; KOEFFLER, H. P. Circadian rhythms and cancer. **Cell cycle**, v. 9, n. 6, p. 1097-1103, 2010.

GRAI, J. *et al.* At the crossroad between obesity and gastric cancer. **Methods in Molecular Biology**, v. 1238, p. 689 - 707, 2015.

HARDEFELDT, P. J.; EDIRIMANNE, S.; ESLICK, G. D. Diabetes increases the risk of breast cancer: a meta-analysis. **Endocrine-related cancer**, v. 19, n. 6, p. 793 – 803, 2012.

HRISTOVA, M. G. Neuroendocrine and immune disequilibrium as a probable link between metabolic syndrome and carcinogenesis. **Medical Hypotheses**, v. 118, p. 1 - 5, 2018.

KANEHISA, M. *et al.* KEGG as a reference resource for gene and protein annotation. **Nucleic Acids Research**, v. 44, p. D457 – D462, 2016.

KARLSSON, B.; KNUTSSON, A.; LINDAHL, B. Is there an association between shift work and having a metabolic syndrome? Results from a population based study of 27 485 people. **Occupational and Environmental Medicine**, v. 58, n. 11, p. 747 – 752, 2001.

KENNAWAY, D. J. *et al.* Functional central rhythmicity and light entrainment, but not liver and muscle rhythmicity, are Clock independent. **Am J Physiol Regul Integr Comp Physiol** v. 291, n. 4, p. 1172 – 1180, 2006.

KOLSTAD, H. A. Nightshift work and risk of breast cancer and other cancers-A critical review of the epidemiologic evidence. **Scandinavian Journal of Work, Environment and Health**, v. 34, n. 1, p. 5 – 22, 2008.

LANDGRAF, D.; SHOSTAK, A.; OSTER, H. Clock genes and sleep. **Pflugers Archiv European Journal of Physiology**, v. 463, n. 1, p. 3 – 14, 2012.

LIGIBEL, J. A.; STRICKLER, H. D. Obesity and Its Impact on Breast Cancer: Tumor Incidence, Recurrence, Survival, and Possible Interventions. **American Society of Clinical Oncology Educational Book**, n. 33, p. 52 – 59, 2013.

LOFRANO, M. C. *et al.* Obesidade e Adipocinas Inflamatórias: Implicações Práticas para a Prescrição de Exercício. **Revista Brasileira De Medicina**, v. 15, n. 1999, p. 378 – 383, 2009.

MARCHEVA, B. *et al.* Disruption of the Clock Components CLOCK and BMAL1 Leads to Hypoinsulinemia and Diabetes. **Nature**, v. 466, n. 7306, p. 627 – 631, 2011.

MAZZOCOLI, G.; PAZIENZA, V.; VINCIGUERRA, M. Clock genes and clock-controlled genes in the regulation of metabolic rhythms. **Chronobiology International**, v. 29, n. 3, p. 227 – 251, 2012.

MENDONÇA, F. M.; DE SOUSA, F. R.; BARBOSA, A. L.; *et al.* Metabolic syndrome and risk of cancer: Which link? **Metabolism: Clinical and Experimental**, v. 64, n. 2, p. 182 – 189, 2015.

MILLER, B. H. *et al.* Circadian and CLOCK-controlled regulation of the mouse transcriptome and cell proliferation. **Proceedings of the National Academy of Sciences of the United States of America**, v. 104, n. 9, p. 3342 – 3347, 2007.

NIRVANI, M. *et al.* Circadian clock and oral cancer (Review). **Molecular and Clinical Oncology**, p. 219 – 226, 2018.

OUCHI, N. *et al.* Adipokines in inflammation and metabolic disease. **Nature Reviews Immunology**, v. 11, p.85 - 97, 2011.

PAL, A. *et al.* PTEN Mutations as a Cause of Constitutive Insulin Sensitivity and Obesity. **New England Journal of Medicine**, v. 367, n. 11, p. 1002 – 1011, 2012.

PEREIRA, L. X. *et al.* Correlation between renin-angiotensin system (RAS) related genes, type 2 diabetes, and cancer: Insights from metanalysis of transcriptomics data. **Molecular and Cellular Endocrinology**, v. 493, p. 1104 - 1155, mar. 2019.

PEREZ, R. O. *et al.* A genética do câncer colorretal: princípios para o cirurgião. **Rev. bras. colo-proctol**, v. 18, n. 1, p. 5 – 10, 1998.

PETERSEN, M. C.; SHULMAN, G. I. Mechanisms of insulin action and insulin resistance. **Physiological Reviews**, v. 98, n. 4, p. 2133 – 2223, 2018.

PRABHAKAR, P. K.; KUMAR, A.; DOBLE, M. Combination therapy: A new strategy to manage diabetes and its complications. **Phytomedicine**, v. 21, n. 2, p. 123 – 130, 2014.

RANA, S.; MAHMOOD, S. Circadian rhythm and its role in malignancy. **Journal of circadian rhythms**, v. 8, n. 1, p. 3, 2010.

RUTTER, J.; REICK, M.; MCKNIGHT, S. L. Metabolism and the control of circadian rhythms. **Annual Review of Biochemistry**, v. 71, p. 307 – 331, 2002.

SAHAR, S.; SASSONE-CORSI, P. Regulation of metabolism: the circadian clock dictates the time. **Trends in Endocrinology & Metabolism**, v. 23, n. 1, p. 1-8, 2012.

SHI, Y. *et al.* PTEN is a protein tyrosine phosphatase for IRS1. **Nature Structural and Molecular Biology**, v. 21, n. 6, p. 522 – 527, 2014.

SINHA, M. K. *et al.* Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. **Journal of Clinical Investigation**, v. 97, n. 5, p. 1344 – 1347, 1996.

ŠKRLEC, I. *et al.* Genetic variations in circadian rhythm genes and susceptibility for myocardial infarction. **Genetics and Molecular Biology**, v. 41, n. 2, p. 403 – 409, 2018.

SOTÁK, M. *et al.* An association between clock genes and clock-controlled cell cycle genes in murine colorectal tumors. **International Journal of Cancer**, v. 132, n. 5, p. 1032 – 1041, 2013.

WONG, K. K. *et al.* Targeting the PI3K signaling pathway in cancer. **Current Opinion in Genetics & Development**, v. 20, p. 87 – 90, 2010.

ZEE, P. C.; ATTARIAN, H.; VIDENOVIC, A. Circadian rhythm abnormalities. **CONTINUUM: Lifelong Learning in Neurology**, v. 19, n. 1, p. 132 – 147, 2013.

ZHU, B. *et al.* The relationship between diabetes and colorectal cancer prognosis: A meta-analysis based on the cohort studies. **PLoS ONE**, v. 12, n. 4, p. 1 – 20, 2017.

ZHU, L.; ZEE, P. C. Circadian Rhythm Sleep Disorders. **Neurol Clin**, v. 30, n. 4, p. 1167 – 1191, 2012.

ANEXO

ANEXO A – Regras para publicação no periódico

GUIDE FOR AUTHORS. Your Paper Your Way We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article. To find out more, please visit the Preparation section below. Types of article • Research Paper • Review Article Unsolicited reviews will be considered only in exceptional cases and should be preceded by a letter of enquiry from the prospective author, who should be a recognized expert in the field of the proposed article. Pre-submission enquiries may be sent to the Editorial Office mce@elsevier.com and will be evaluated by the Special Issues and Reviews Editor of Molecular and Cellular Endocrinology. Specifically, authors must provide the following in their review proposal: 1) both your own and any co-author(s) affiliation and full contact details; 2) an explanation of the current interest and significance to the broad readership of the journal, that is, compelling reasons why the review should be considered; 3) a 500-600 word summary which clearly outlines what will be discussed in the article, plus up to 20 key references that indicate the intended breadth of the proposed article (please note that references should include work published in the past 2-4 years). Only proposals that include this information will be considered.

Submission checklist You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details. Ensure that the following items are present: One author has been designated as the corresponding author with contact details: • E-mail address • Full postal address All necessary files have been uploaded: Manuscript: • Include keywords • All figures (include relevant captions) • All tables (including titles, description, footnotes) • Ensure all figure and table citations in the text match the files provided • Indicate clearly if color should be used for any figures in print Graphical Abstracts / Highlights files (where applicable) Supplemental files (where applicable) Further considerations • Manuscript has been 'spell checked' and 'grammar checked' • All references mentioned in the Reference List are cited in the text, and vice versa • Permission has been obtained for use of copyrighted material from other sources (including the Internet) • A competing interests statement is provided, even if the authors have no competing

interests to declare • Journal policies detailed in this guide have been reviewed • Referee suggestions and contact details provided, based on journal requirements For further information, visit our Support Center. BEFORE YOU BEGIN Ethics in publishing Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.

Studies in humans and animals If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed. All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

Declaration of interest All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double anonymized) or the manuscript file (if single anonymized). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. More information.

Submission declaration and verification Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is

approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check. Preprints Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information). Use of inclusive language inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive. Author contributions for transparency, we encourage authors to submit an author statement file outlining their individual contributions to the paper using the relevant CRediT roles: Conceptualization; Data curation; formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Authorship statements should be formatted with the names of authors first and credit role(s) following. More details and an example

Changes to authorship Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or

rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Only in exceptional circumstances will the editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the editor will result in a corrigendum. Article transfer service This journal is part of our Article Transfer Service. This means that if the editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. More information. Copyright Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement. Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases. For gold open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license. Author rights As an author you (or your employer or institution) have certain rights to reuse your work. More information. Elsevier supports responsible sharing Find out how you can share your research published in Elsevier journals. Role of the funding source You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated. Open access Please visit our Open Access page for more information

Elsevier Researcher Academy Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars,

downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

Language (usage and editing services) Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's Author Services.

Submission Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Referees Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our Support site. Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

PREPARATION NEW SUBMISSIONS Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process. As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

References There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/ book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

Formatting requirements There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions. If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes. Divide the article into clearly defined

sections. Figures and tables embedded in text Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should be placed directly below the figure or table. Peer review This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

REVISED SUBMISSIONS Use of word processing software Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). See also the section on Electronic artwork. To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure Subdivision - numbered sections divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Introduction State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Theory/calculation A Theory section should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work. In contrast, a Calculation section represents a practical development from a theoretical basis.

Results Results should be clear and concise.

Discussion This should explore the significance of the results of

the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature. Conclusions The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section. Appendices If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

Essential title page information

- Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

- Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.
- Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Highlights are mandatory for this journal as they help increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: [example Highlights](#). Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

Abstract A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon

abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself. The abstract should be no more than 150 words. Graphical abstract Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531×1328 pixels (h \times w) or proportionally more. The image should be readable at a size of 5×13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site. Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images and in accordance with all technical requirements. Keywords Immediately after the abstract, provide a maximum of 6 keywords, using British spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes. Abbreviations Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article. Acknowledgements Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.). Formatting of funding sources List funding sources in this standard way to facilitate compliance to funder's requirements: Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding. If no funding has been provided for the research, please include the following sentence: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Units Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI. Math formulae Please submit math equations as editable text and not as

images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text). Footnotes Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article. Artwork Image Manipulation Whilst it is accepted that authors sometimes need to manipulate images for clarity, manipulation for purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with accordingly. For graphical images, this journal is applying the following policy: no specific feature within an image may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast, or color balance are acceptable if and as long as they do not obscure or eliminate any information present in the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed in the figure legend. Electronic artwork General points • Make sure you use uniform lettering and sizing of your original artwork. • Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier. • Number the illustrations according to their sequence in the text. • Use a logical naming convention for your artwork files. • Indicate per figure if it is a single, 1.5 or 2-column fitting image. • For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage. • Please note that individual figure files larger than 10 MB must be provided in separate source files. A detailed guide on electronic artwork is available. You are urged to visit this site; some excerpts from the detailed information are given here. Formats Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below): EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'. TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi. TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi. TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required. Please do not: • Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low. • Supply files that are too low in resolution. • Submit graphics that are disproportionately large for the content.

Color artwork Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) in addition to color reproduction in print. Further information on the preparation of electronic artwork. **Illustration services** Elsevier's Author Services offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more. **Figure captions** Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used. **Tables** Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells. **References** **Citation in text** Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication. **Reference links** Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged. A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab

beneath northeastern Venezuela. Journal of Geophysical Research, <https://doi.org/10.1029/2001JB000884>. Please note the format of such citations should be in the same style as all other references in the paper. Web references As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list. Data references This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

References in a special issue Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue. Reference management software Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plugins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software. Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link: <http://open.mendeley.com/use-citation-style/molecular-and-cellular-endocrinology> When preparing your manuscript, you will then be able to select this style using the Mendeley plugins for Microsoft Word or LibreOffice. Reference formatting There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/ book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the

following examples: Reference style Text: All citations in the text should refer to: 1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication; 2. Two authors: both authors' names and the year of publication; 3. Three or more authors: first author's name followed by 'et al.' and the year of publication. Citations may be made directly (or parenthetically). Groups of references can be listed either first alphabetically, then chronologically, or vice versa. Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999) Or, as demonstrated (Jones, 1999; Allan, 2000) ... Kramer et al. (2010) have recently shown ...' List: References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication. Examples: Reference to a journal publication: Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2010. The art of writing a scientific article. *J. Sci. Commun.* 163, 51–59. <https://doi.org/10.1016/j.Sc.2010.00372>. Reference to a journal publication with an article number: Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2018. The art of writing a scientific article. *Heliyon.* 19, e00205. <https://doi.org/10.1016/j.heliyon.2018.e00205>. Reference to a book: Strunk Jr., W., White, E.B., 2000. *The Elements of Style*, fourth ed. Longman, New York. Reference to a chapter in an edited book: Mettam, G.R., Adams, L.B., 2009. How to prepare an electronic version of your article, in: Jones, B.S., Smith, R.Z. (Eds.), *Introduction to the Electronic Age*. E-Publishing Inc., New York, pp. 281–304. Reference to a website: Cancer Research UK, 1975. Cancer statistics reports for the UK. <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/> (accessed 13 March 2003). Reference to a dataset: [dataset] Oguro, M., Imahiro, S., Saito, S., Nakashizuka, T., 2015. Mortality data for Japanese oak wilt disease and surrounding forest compositions. *Mendeley Data*, v1. <https://doi.org/10.17632/xwj98nb39r.1>. Journal abbreviations source Journal names should be abbreviated according to the List of Title Word Abbreviations. Video Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including

ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Data visualization Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

Supplementary material Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

Research data This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project. Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

Data linking If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described. There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page. For supported data repositories a repository banner will automatically appear next to your published article on

ScienceDirect. In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

Mendeley Data This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley Data. The datasets will be listed and directly accessible to readers next to your published article online. For more information, visit the [Mendeley Data for journals page](#).

Data in Brief You have the option of converting any or all parts of your supplementary or additional raw data into a data article published in Data in Brief. A data article is a new kind of article that ensures that your data are actively reviewed, curated, formatted, indexed, given a DOI and made publicly available to all upon publication (watch this [video](#) describing the benefits of publishing your data in Data in Brief). You are encouraged to submit your data article for Data in Brief as an additional item directly alongside the revised version of your manuscript. If your research article is accepted, your data article will automatically be transferred over to Data in Brief where it will be editorially reviewed, published open access and linked to your research article on ScienceDirect. Please note an open access fee is payable for publication in Data in Brief. Full details can be found on the [Data in Brief website](#). Please use this [template](#) to write your Data in Brief data article.

Data statement to foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

AFTER ACCEPTANCE Online proof correction to ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors. If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors,

including alternative methods to the online version and PDF. We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Offprints The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Author Services. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link. AUTHOR INQUIRIES Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch. You can also check the status of your submitted article or find out when your accepted article will be published.